WO2008151035A2 - Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds) - Google Patents
Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds) Download PDFInfo
- Publication number
- WO2008151035A2 WO2008151035A2 PCT/US2008/065349 US2008065349W WO2008151035A2 WO 2008151035 A2 WO2008151035 A2 WO 2008151035A2 US 2008065349 W US2008065349 W US 2008065349W WO 2008151035 A2 WO2008151035 A2 WO 2008151035A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sall4
- cells
- cell
- expression
- seq
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 35
- 201000003793 Myelodysplastic syndrome Diseases 0.000 title abstract description 89
- 238000011282 treatment Methods 0.000 title description 22
- 230000002062 proliferating effect Effects 0.000 title description 13
- 230000008685 targeting Effects 0.000 title description 13
- 238000003745 diagnosis Methods 0.000 title description 8
- 101000740178 Homo sapiens Sal-like protein 4 Proteins 0.000 claims abstract description 529
- 102100037192 Sal-like protein 4 Human genes 0.000 claims abstract description 515
- 210000004027 cell Anatomy 0.000 claims abstract description 469
- 230000014509 gene expression Effects 0.000 claims abstract description 215
- 238000000034 method Methods 0.000 claims abstract description 113
- 210000000130 stem cell Anatomy 0.000 claims abstract description 105
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 53
- 201000011510 cancer Diseases 0.000 claims abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 197
- 230000000694 effects Effects 0.000 claims description 90
- 210000001519 tissue Anatomy 0.000 claims description 68
- 230000004069 differentiation Effects 0.000 claims description 45
- 239000003795 chemical substances by application Substances 0.000 claims description 39
- 239000013598 vector Substances 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 32
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 25
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 24
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 24
- 230000011987 methylation Effects 0.000 claims description 15
- 238000007069 methylation reaction Methods 0.000 claims description 15
- 208000021309 Germ cell tumor Diseases 0.000 claims description 12
- 238000002054 transplantation Methods 0.000 claims description 12
- 206010043276 Teratoma Diseases 0.000 claims description 10
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 10
- 229960001467 bortezomib Drugs 0.000 claims description 10
- 201000009051 Embryonal Carcinoma Diseases 0.000 claims description 9
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 8
- 201000010208 Seminoma Diseases 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 8
- 230000005291 magnetic effect Effects 0.000 claims description 8
- 239000003207 proteasome inhibitor Substances 0.000 claims description 8
- 230000002381 testicular Effects 0.000 claims description 8
- 208000001991 endodermal sinus tumor Diseases 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- GEBBCNXOYOVGQS-BNHYGAARSA-N 4-amino-1-[(2r,3r,4s,5s)-3,4-dihydroxy-5-(hydroxyamino)oxolan-2-yl]pyrimidin-2-one Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](NO)O1 GEBBCNXOYOVGQS-BNHYGAARSA-N 0.000 claims description 6
- 206010073118 Spermatocytic seminoma Diseases 0.000 claims description 6
- 201000009686 spermatocytoma Diseases 0.000 claims description 6
- 108010065472 Vimentin Proteins 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 5
- 210000005048 vimentin Anatomy 0.000 claims description 5
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 claims description 4
- 108010051457 Acid Phosphatase Proteins 0.000 claims description 4
- 102000013563 Acid Phosphatase Human genes 0.000 claims description 4
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 4
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 4
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 4
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 4
- 208000012018 Yolk sac tumor Diseases 0.000 claims description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 4
- 208000023525 immature teratoma Diseases 0.000 claims description 4
- 201000000289 malignant teratoma Diseases 0.000 claims description 4
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims description 4
- IUGJLFDBGMJTLH-SKNVOMKLSA-N 4-amino-1-[(2R,3R,4S,5S)-3,4-dihydroxy-5-(trihydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound OC([C@@H]1[C@H]([C@H]([C@@H](O1)N1C(=O)N=C(N)N=C1)O)O)(O)O IUGJLFDBGMJTLH-SKNVOMKLSA-N 0.000 claims description 3
- 101000662049 Homo sapiens Polyubiquitin-C Proteins 0.000 claims description 3
- DAQAKHDKYAWHCG-UHFFFAOYSA-N Lactacystin Natural products CC(=O)NC(C(O)=O)CSC(=O)C1(C(O)C(C)C)NC(=O)C(C)C1O DAQAKHDKYAWHCG-UHFFFAOYSA-N 0.000 claims description 3
- 102100037935 Polyubiquitin-C Human genes 0.000 claims description 3
- DOGIDQKFVLKMLQ-JTHVHQAWSA-N epoxomicin Chemical compound CC[C@H](C)[C@H](N(C)C(C)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 DOGIDQKFVLKMLQ-JTHVHQAWSA-N 0.000 claims description 3
- 108700002672 epoxomicin Proteins 0.000 claims description 3
- 210000004700 fetal blood Anatomy 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- DAQAKHDKYAWHCG-RWTHQLGUSA-N lactacystin Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 claims description 3
- 210000003954 umbilical cord Anatomy 0.000 claims description 3
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 1
- 229940079131 Methylase inhibitor Drugs 0.000 claims 1
- 102000013127 Vimentin Human genes 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract description 126
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract description 119
- 102000004169 proteins and genes Human genes 0.000 abstract description 72
- 238000011830 transgenic mouse model Methods 0.000 abstract description 70
- 241000699660 Mus musculus Species 0.000 abstract description 63
- 108010029485 Protein Isoforms Proteins 0.000 abstract description 29
- 102000001708 Protein Isoforms Human genes 0.000 abstract description 29
- 150000007523 nucleic acids Chemical class 0.000 abstract description 28
- 208000032839 leukemia Diseases 0.000 abstract description 23
- 241001465754 Metazoa Species 0.000 abstract description 22
- 102000039446 nucleic acids Human genes 0.000 abstract description 21
- 108020004707 nucleic acids Proteins 0.000 abstract description 21
- 210000001671 embryonic stem cell Anatomy 0.000 abstract description 18
- 206010000830 Acute leukaemia Diseases 0.000 abstract description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 9
- 208000036676 acute undifferentiated leukemia Diseases 0.000 abstract description 9
- 229910052725 zinc Inorganic materials 0.000 abstract description 9
- 239000011701 zinc Substances 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 8
- 210000004504 adult stem cell Anatomy 0.000 abstract description 6
- 230000002103 transcriptional effect Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 4
- 108091005461 Nucleic proteins Proteins 0.000 abstract description 3
- 230000002122 leukaemogenic effect Effects 0.000 abstract description 3
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 155
- 241000699670 Mus sp. Species 0.000 description 62
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 62
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 61
- 210000001185 bone marrow Anatomy 0.000 description 58
- 230000027455 binding Effects 0.000 description 49
- 230000001965 increasing effect Effects 0.000 description 43
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 41
- 239000000523 sample Substances 0.000 description 38
- 102000015735 Beta-catenin Human genes 0.000 description 36
- 108060000903 Beta-catenin Proteins 0.000 description 36
- 230000006907 apoptotic process Effects 0.000 description 36
- 230000018109 developmental process Effects 0.000 description 36
- 238000011161 development Methods 0.000 description 35
- 108700005087 Homeobox Genes Proteins 0.000 description 34
- 150000001413 amino acids Chemical group 0.000 description 34
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 32
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 32
- 108090000765 processed proteins & peptides Proteins 0.000 description 32
- 108020004459 Small interfering RNA Proteins 0.000 description 31
- 108020004999 messenger RNA Proteins 0.000 description 31
- 239000012634 fragment Substances 0.000 description 30
- 239000013612 plasmid Substances 0.000 description 27
- 230000001105 regulatory effect Effects 0.000 description 27
- 102000004196 processed proteins & peptides Human genes 0.000 description 26
- 229920001184 polypeptide Polymers 0.000 description 25
- 102000013814 Wnt Human genes 0.000 description 24
- 108050003627 Wnt Proteins 0.000 description 24
- 238000003752 polymerase chain reaction Methods 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- 238000003556 assay Methods 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 22
- 238000010186 staining Methods 0.000 description 21
- 230000009261 transgenic effect Effects 0.000 description 21
- -1 Gr-I Proteins 0.000 description 20
- 230000037361 pathway Effects 0.000 description 20
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 19
- 230000004913 activation Effects 0.000 description 19
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 19
- 230000003993 interaction Effects 0.000 description 19
- 210000005259 peripheral blood Anatomy 0.000 description 19
- 239000011886 peripheral blood Substances 0.000 description 19
- 102000040430 polynucleotide Human genes 0.000 description 19
- 108091033319 polynucleotide Proteins 0.000 description 19
- 239000002157 polynucleotide Substances 0.000 description 19
- 102000003952 Caspase 3 Human genes 0.000 description 18
- 108090000397 Caspase 3 Proteins 0.000 description 18
- 108060001084 Luciferase Proteins 0.000 description 18
- 239000005089 Luciferase Substances 0.000 description 18
- 238000011529 RT qPCR Methods 0.000 description 18
- 102000040945 Transcription factor Human genes 0.000 description 18
- 108091023040 Transcription factor Proteins 0.000 description 18
- 230000009466 transformation Effects 0.000 description 18
- 230000025084 cell cycle arrest Effects 0.000 description 17
- 230000000295 complement effect Effects 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 17
- 230000009467 reduction Effects 0.000 description 17
- 238000001890 transfection Methods 0.000 description 17
- 239000002299 complementary DNA Substances 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 241000700605 Viruses Species 0.000 description 15
- 239000012472 biological sample Substances 0.000 description 15
- 210000002798 bone marrow cell Anatomy 0.000 description 15
- 230000003247 decreasing effect Effects 0.000 description 15
- 210000001900 endoderm Anatomy 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 239000003550 marker Substances 0.000 description 15
- 210000002569 neuron Anatomy 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 238000003753 real-time PCR Methods 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 230000019491 signal transduction Effects 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 210000002304 esc Anatomy 0.000 description 14
- 230000002018 overexpression Effects 0.000 description 14
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 13
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 13
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 13
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 210000003981 ectoderm Anatomy 0.000 description 13
- 210000000265 leukocyte Anatomy 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 230000006820 DNA synthesis Effects 0.000 description 12
- 101710154606 Hemagglutinin Proteins 0.000 description 12
- 241001529936 Murinae Species 0.000 description 12
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 12
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 12
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 12
- 101710176177 Protein A56 Proteins 0.000 description 12
- 239000000185 hemagglutinin Substances 0.000 description 12
- 230000011132 hemopoiesis Effects 0.000 description 12
- 238000003364 immunohistochemistry Methods 0.000 description 12
- 201000009030 Carcinoma Diseases 0.000 description 11
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 11
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 11
- 101150062997 Rnf2 gene Proteins 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 108010033040 Histones Proteins 0.000 description 10
- 101100364841 Homo sapiens SALL4 gene Proteins 0.000 description 10
- 102000018697 Membrane Proteins Human genes 0.000 description 10
- 108010052285 Membrane Proteins Proteins 0.000 description 10
- 101150041225 SALL4 gene Proteins 0.000 description 10
- 230000003321 amplification Effects 0.000 description 10
- 230000033228 biological regulation Effects 0.000 description 10
- 230000022131 cell cycle Effects 0.000 description 10
- 230000024245 cell differentiation Effects 0.000 description 10
- 230000004663 cell proliferation Effects 0.000 description 10
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 10
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 10
- 210000002360 granulocyte-macrophage progenitor cell Anatomy 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 210000003716 mesoderm Anatomy 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 238000003491 array Methods 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 229930002330 retinoic acid Natural products 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 229960001727 tretinoin Drugs 0.000 description 9
- 241001430294 unidentified retrovirus Species 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 241000242739 Renilla Species 0.000 description 8
- 101100465401 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SCL1 gene Proteins 0.000 description 8
- 210000001789 adipocyte Anatomy 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 230000000925 erythroid effect Effects 0.000 description 8
- 201000011066 hemangioma Diseases 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 208000025113 myeloid leukemia Diseases 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 7
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 7
- 101000740180 Homo sapiens Sal-like protein 3 Proteins 0.000 description 7
- 102100037191 Sal-like protein 3 Human genes 0.000 description 7
- 230000001594 aberrant effect Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000003828 downregulation Effects 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 210000004602 germ cell Anatomy 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000003394 haemopoietic effect Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 230000003211 malignant effect Effects 0.000 description 7
- 230000001613 neoplastic effect Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 230000003827 upregulation Effects 0.000 description 7
- 108091093088 Amplicon Proteins 0.000 description 6
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 6
- 206010061818 Disease progression Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 101710172711 Structural protein Proteins 0.000 description 6
- 229950004398 broxuridine Drugs 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000001612 chondrocyte Anatomy 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 230000005750 disease progression Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000013020 embryo development Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000002489 hematologic effect Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 210000004153 islets of langerhan Anatomy 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 210000003593 megakaryocyte Anatomy 0.000 description 6
- 210000004248 oligodendroglia Anatomy 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 108010077544 Chromatin Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 108010066805 F-Box Proteins Proteins 0.000 description 5
- 102000018700 F-Box Proteins Human genes 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000004156 Wnt signaling pathway Effects 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 108091092356 cellular DNA Proteins 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 210000003483 chromatin Anatomy 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- 102000050478 human SALL4 Human genes 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000000520 microinjection Methods 0.000 description 5
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 5
- 238000012758 nuclear staining Methods 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 210000000287 oocyte Anatomy 0.000 description 5
- 210000000963 osteoblast Anatomy 0.000 description 5
- 210000001778 pluripotent stem cell Anatomy 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 4
- 102100026189 Beta-galactosidase Human genes 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 238000007450 ChIP-chip Methods 0.000 description 4
- 201000000913 Duane retraction syndrome Diseases 0.000 description 4
- 201000001355 Duane-radial ray syndrome Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 208000031785 Okihiro syndrome Diseases 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 206010033661 Pancytopenia Diseases 0.000 description 4
- 241000233805 Phoenix Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108010052090 Renilla Luciferases Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 102100035071 Vimentin Human genes 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 210000003969 blast cell Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000001654 germ layer Anatomy 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000000107 myocyte Anatomy 0.000 description 4
- 210000005170 neoplastic cell Anatomy 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 208000004860 Blast Crisis Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 108700029231 Developmental Genes Proteins 0.000 description 3
- 101100477411 Dictyostelium discoideum set1 gene Proteins 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 3
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 3
- 230000010337 G2 phase Effects 0.000 description 3
- 208000034951 Genetic Translocation Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 101100364842 Mus musculus Sall4 gene Proteins 0.000 description 3
- 238000011789 NOD SCID mouse Methods 0.000 description 3
- 102000008730 Nestin Human genes 0.000 description 3
- 108010088225 Nestin Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 108010022429 Polycomb-Group Proteins Proteins 0.000 description 3
- 102000012425 Polycomb-Group Proteins Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000002788 anti-peptide Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 230000003831 deregulation Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000013265 extended release Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000003963 intermediate filament Anatomy 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000000271 mature teratoma Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 210000001087 myotubule Anatomy 0.000 description 3
- 210000005055 nestin Anatomy 0.000 description 3
- 210000001020 neural plate Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 210000004789 organ system Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000002863 seminiferous tubule Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000010599 BrdU assay Methods 0.000 description 2
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 2
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108010051152 Carboxylesterase Proteins 0.000 description 2
- 102000013392 Carboxylesterase Human genes 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000002585 Contractile Proteins Human genes 0.000 description 2
- 108010068426 Contractile Proteins Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 2
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 2
- 101710118908 Fatty acid-binding protein, adipocyte Proteins 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 102100037060 Forkhead box protein D3 Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102100033636 Histone H3.2 Human genes 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101001029308 Homo sapiens Forkhead box protein D3 Proteins 0.000 description 2
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010069360 Leukaemic infiltration Diseases 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 2
- 102000008763 Neurofilament Proteins Human genes 0.000 description 2
- 108010088373 Neurofilament Proteins Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102000004067 Osteocalcin Human genes 0.000 description 2
- 108090000573 Osteocalcin Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000012288 TUNEL assay Methods 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108091007916 Zinc finger transcription factors Proteins 0.000 description 2
- 102000038627 Zinc finger transcription factors Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 208000013685 acquired idiopathic sideroblastic anemia Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000005775 apoptotic pathway Effects 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000002960 bfu-e Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000006369 cell cycle progression Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 208000024389 cytopenia Diseases 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 210000002242 embryoid body Anatomy 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 108091022862 fatty acid binding Proteins 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 101150003286 gata4 gene Proteins 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000012145 high-salt buffer Substances 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000008611 intercellular interaction Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000003468 luciferase reporter gene assay Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000001002 morphogenetic effect Effects 0.000 description 2
- 210000001665 muscle stem cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 210000005044 neurofilament Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011536 re-plating Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000713826 Avian leukosis virus Species 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 102100028625 Brain-specific homeobox protein homolog Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102000008749 CID domains Human genes 0.000 description 1
- 108050000533 CID domains Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 description 1
- 101100313164 Caenorhabditis elegans sea-1 gene Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101150006631 DBX1 gene Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100031257 Diencephalon/mesencephalon homeobox protein 1 Human genes 0.000 description 1
- 101150118728 Dlx5 gene Proteins 0.000 description 1
- 101100295848 Drosophila melanogaster Optix gene Proteins 0.000 description 1
- 108700032111 Drosophila salm Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 1
- 102100040620 Dynein regulatory complex subunit 6 Human genes 0.000 description 1
- 101710095704 Dynein regulatory complex subunit 6 Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102100022113 F-box only protein 28 Human genes 0.000 description 1
- 102100040643 F-box only protein 36 Human genes 0.000 description 1
- 101710191015 F-box only protein 36 Proteins 0.000 description 1
- 102100026079 F-box only protein 42 Human genes 0.000 description 1
- 102100029186 F-box only protein 9 Human genes 0.000 description 1
- 101710199745 F-box only protein 9 Proteins 0.000 description 1
- 102100027728 F-box/LRR-repeat protein 18 Human genes 0.000 description 1
- 101710126388 F-box/LRR-repeat protein 21 Proteins 0.000 description 1
- 102100038580 F-box/WD repeat-containing protein 10 Human genes 0.000 description 1
- 102100038575 F-box/WD repeat-containing protein 12 Human genes 0.000 description 1
- 102100040672 F-box/WD repeat-containing protein 9 Human genes 0.000 description 1
- 101150020690 FBXL21 gene Proteins 0.000 description 1
- 101150024944 FBXO9 gene Proteins 0.000 description 1
- 101150106966 FOXO1 gene Proteins 0.000 description 1
- 101100058548 Felis catus BMI1 gene Proteins 0.000 description 1
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102100021084 Forkhead box protein C1 Human genes 0.000 description 1
- 102100037043 Forkhead box protein D4 Human genes 0.000 description 1
- 102100020848 Forkhead box protein F2 Human genes 0.000 description 1
- 102100020871 Forkhead box protein G1 Human genes 0.000 description 1
- 102100041002 Forkhead box protein H1 Human genes 0.000 description 1
- 102100035134 Forkhead box protein J2 Human genes 0.000 description 1
- 102100023367 Forkhead box protein N4 Human genes 0.000 description 1
- 102100028115 Forkhead box protein P2 Human genes 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 102100027580 Forkhead box protein R2 Human genes 0.000 description 1
- 101150019145 Foxd4 gene Proteins 0.000 description 1
- 101150075185 Foxp2 gene Proteins 0.000 description 1
- 102100033924 GS homeobox 2 Human genes 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- 108700005000 Glial Fibrillary Acidic Proteins 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102100027490 H2.0-like homeobox protein Human genes 0.000 description 1
- 101150065642 HOXA4 gene Proteins 0.000 description 1
- 101150032268 HOXB7 gene Proteins 0.000 description 1
- 101150067554 HOXD3 gene Proteins 0.000 description 1
- 102100034676 Hepatocyte cell adhesion molecule Human genes 0.000 description 1
- 101710122896 Hepatocyte cell adhesion molecule Proteins 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 101150068639 Hnf4a gene Proteins 0.000 description 1
- 102100031670 Homeobox protein CDX-4 Human genes 0.000 description 1
- 102100021154 Homeobox protein DBX1 Human genes 0.000 description 1
- 102100030087 Homeobox protein DLX-1 Human genes 0.000 description 1
- 102100022373 Homeobox protein DLX-5 Human genes 0.000 description 1
- 102100031800 Homeobox protein ESX1 Human genes 0.000 description 1
- 102100030309 Homeobox protein Hox-A1 Human genes 0.000 description 1
- 102100030308 Homeobox protein Hox-A11 Human genes 0.000 description 1
- 102100039541 Homeobox protein Hox-A3 Human genes 0.000 description 1
- 102100025116 Homeobox protein Hox-A4 Human genes 0.000 description 1
- 102100025110 Homeobox protein Hox-A5 Human genes 0.000 description 1
- 102100022650 Homeobox protein Hox-A7 Human genes 0.000 description 1
- 102100021090 Homeobox protein Hox-A9 Human genes 0.000 description 1
- 102100034862 Homeobox protein Hox-B2 Human genes 0.000 description 1
- 102100029240 Homeobox protein Hox-B5 Human genes 0.000 description 1
- 102100025056 Homeobox protein Hox-B6 Human genes 0.000 description 1
- 102100025061 Homeobox protein Hox-B7 Human genes 0.000 description 1
- 102100029423 Homeobox protein Hox-B8 Human genes 0.000 description 1
- 102100029426 Homeobox protein Hox-C10 Human genes 0.000 description 1
- 102100020766 Homeobox protein Hox-C11 Human genes 0.000 description 1
- 102100020759 Homeobox protein Hox-C4 Human genes 0.000 description 1
- 102100022599 Homeobox protein Hox-C6 Human genes 0.000 description 1
- 102100022597 Homeobox protein Hox-C9 Human genes 0.000 description 1
- 102100039544 Homeobox protein Hox-D10 Human genes 0.000 description 1
- 102100040205 Homeobox protein Hox-D12 Human genes 0.000 description 1
- 102100040228 Homeobox protein Hox-D3 Human genes 0.000 description 1
- 102100021086 Homeobox protein Hox-D4 Human genes 0.000 description 1
- 102100037102 Homeobox protein MOX-2 Human genes 0.000 description 1
- 101710142888 Homeobox protein MOX-2 Proteins 0.000 description 1
- 102100029330 Homeobox protein PKNOX2 Human genes 0.000 description 1
- 102100040188 Homeobox protein unc-4 homolog Human genes 0.000 description 1
- 102100028171 Homeobox-containing protein 1 Human genes 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102100028798 Homeodomain-only protein Human genes 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000695012 Homo sapiens Brain-specific homeobox protein homolog Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000844735 Homo sapiens Diencephalon/mesencephalon homeobox protein 1 Proteins 0.000 description 1
- 101000824152 Homo sapiens F-box only protein 28 Proteins 0.000 description 1
- 101000913306 Homo sapiens F-box only protein 42 Proteins 0.000 description 1
- 101000862204 Homo sapiens F-box/LRR-repeat protein 18 Proteins 0.000 description 1
- 101001030688 Homo sapiens F-box/WD repeat-containing protein 10 Proteins 0.000 description 1
- 101001030693 Homo sapiens F-box/WD repeat-containing protein 12 Proteins 0.000 description 1
- 101000892315 Homo sapiens F-box/WD repeat-containing protein 9 Proteins 0.000 description 1
- 101000818727 Homo sapiens Forkhead box protein B1 Proteins 0.000 description 1
- 101000818310 Homo sapiens Forkhead box protein C1 Proteins 0.000 description 1
- 101001029302 Homo sapiens Forkhead box protein D4 Proteins 0.000 description 1
- 101000931482 Homo sapiens Forkhead box protein F2 Proteins 0.000 description 1
- 101000931525 Homo sapiens Forkhead box protein G1 Proteins 0.000 description 1
- 101000892840 Homo sapiens Forkhead box protein H1 Proteins 0.000 description 1
- 101001023384 Homo sapiens Forkhead box protein J2 Proteins 0.000 description 1
- 101000907587 Homo sapiens Forkhead box protein N4 Proteins 0.000 description 1
- 101001059881 Homo sapiens Forkhead box protein P2 Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101000861391 Homo sapiens Forkhead box protein R2 Proteins 0.000 description 1
- 101001068302 Homo sapiens GS homeobox 2 Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 101001081101 Homo sapiens H2.0-like homeobox protein Proteins 0.000 description 1
- 101000777790 Homo sapiens Homeobox protein CDX-4 Proteins 0.000 description 1
- 101001041021 Homo sapiens Homeobox protein DBX1 Proteins 0.000 description 1
- 101000901627 Homo sapiens Homeobox protein DLX-5 Proteins 0.000 description 1
- 101000920856 Homo sapiens Homeobox protein ESX1 Proteins 0.000 description 1
- 101001083156 Homo sapiens Homeobox protein Hox-A1 Proteins 0.000 description 1
- 101001083158 Homo sapiens Homeobox protein Hox-A11 Proteins 0.000 description 1
- 101000962622 Homo sapiens Homeobox protein Hox-A3 Proteins 0.000 description 1
- 101001077578 Homo sapiens Homeobox protein Hox-A4 Proteins 0.000 description 1
- 101001077568 Homo sapiens Homeobox protein Hox-A5 Proteins 0.000 description 1
- 101001045116 Homo sapiens Homeobox protein Hox-A7 Proteins 0.000 description 1
- 101001041174 Homo sapiens Homeobox protein Hox-A9 Proteins 0.000 description 1
- 101001019752 Homo sapiens Homeobox protein Hox-B2 Proteins 0.000 description 1
- 101000840553 Homo sapiens Homeobox protein Hox-B5 Proteins 0.000 description 1
- 101001077542 Homo sapiens Homeobox protein Hox-B6 Proteins 0.000 description 1
- 101001077539 Homo sapiens Homeobox protein Hox-B7 Proteins 0.000 description 1
- 101000988994 Homo sapiens Homeobox protein Hox-B8 Proteins 0.000 description 1
- 101000989027 Homo sapiens Homeobox protein Hox-C10 Proteins 0.000 description 1
- 101001003015 Homo sapiens Homeobox protein Hox-C11 Proteins 0.000 description 1
- 101001002994 Homo sapiens Homeobox protein Hox-C4 Proteins 0.000 description 1
- 101001045154 Homo sapiens Homeobox protein Hox-C6 Proteins 0.000 description 1
- 101001045140 Homo sapiens Homeobox protein Hox-C9 Proteins 0.000 description 1
- 101000962573 Homo sapiens Homeobox protein Hox-D10 Proteins 0.000 description 1
- 101001037169 Homo sapiens Homeobox protein Hox-D12 Proteins 0.000 description 1
- 101001037158 Homo sapiens Homeobox protein Hox-D3 Proteins 0.000 description 1
- 101001041136 Homo sapiens Homeobox protein Hox-D4 Proteins 0.000 description 1
- 101001125949 Homo sapiens Homeobox protein PKNOX2 Proteins 0.000 description 1
- 101000747380 Homo sapiens Homeobox protein unc-4 homolog Proteins 0.000 description 1
- 101001006354 Homo sapiens Homeobox-containing protein 1 Proteins 0.000 description 1
- 101000839095 Homo sapiens Homeodomain-only protein Proteins 0.000 description 1
- 101000613575 Homo sapiens Paired box protein Pax-1 Proteins 0.000 description 1
- 101000735484 Homo sapiens Paired box protein Pax-9 Proteins 0.000 description 1
- 101001069723 Homo sapiens Paired mesoderm homeobox protein 2 Proteins 0.000 description 1
- 101001069749 Homo sapiens Prospero homeobox protein 1 Proteins 0.000 description 1
- 101000740204 Homo sapiens Sal-like protein 2 Proteins 0.000 description 1
- 101000946163 Homo sapiens Transcription factor LBX2 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000723833 Homo sapiens Zinc finger E-box-binding homeobox 2 Proteins 0.000 description 1
- 101150013773 Hoxa7 gene Proteins 0.000 description 1
- 101150015534 Hoxc4 gene Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 101150040658 LHX2 gene Proteins 0.000 description 1
- 108010022677 LIM homeobox protein 8 Proteins 0.000 description 1
- 102100036132 LIM/homeobox protein Lhx2 Human genes 0.000 description 1
- 101710135156 LIM/homeobox protein Lhx2 Proteins 0.000 description 1
- 102100036106 LIM/homeobox protein Lhx3 Human genes 0.000 description 1
- 101710135020 LIM/homeobox protein Lhx3 Proteins 0.000 description 1
- 102100022136 LIM/homeobox protein Lhx8 Human genes 0.000 description 1
- 102100022141 LIM/homeobox protein Lhx9 Human genes 0.000 description 1
- 101710134947 LIM/homeobox protein Lhx9 Proteins 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010062489 Leukaemia recurrent Diseases 0.000 description 1
- 108700042694 Lhx3 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100040584 Lysine-specific demethylase 2B Human genes 0.000 description 1
- 101710105679 Lysine-specific demethylase 2B Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- 101150118570 Msx2 gene Proteins 0.000 description 1
- 101100220214 Mus musculus Cdx4 gene Proteins 0.000 description 1
- 101100172780 Mus musculus Evx2 gene Proteins 0.000 description 1
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 description 1
- 101100125257 Mus musculus Hoxa3 gene Proteins 0.000 description 1
- 101100451924 Mus musculus Hoxb6 gene Proteins 0.000 description 1
- 101100507946 Mus musculus Hoxc9 gene Proteins 0.000 description 1
- 101100340130 Mus musculus Hoxd1 gene Proteins 0.000 description 1
- 101100340122 Mus musculus Hoxd12 gene Proteins 0.000 description 1
- 101100178955 Mus musculus Hoxd4 gene Proteins 0.000 description 1
- 101001033276 Mus musculus Interleukin-3 Proteins 0.000 description 1
- 101100179988 Mus musculus Irx2 gene Proteins 0.000 description 1
- 101000942966 Mus musculus Leukemia inhibitory factor Proteins 0.000 description 1
- 101100518987 Mus musculus Pax1 gene Proteins 0.000 description 1
- 101100518992 Mus musculus Pax2 gene Proteins 0.000 description 1
- 101100518997 Mus musculus Pax3 gene Proteins 0.000 description 1
- 101100351033 Mus musculus Pax7 gene Proteins 0.000 description 1
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 206010067387 Myelodysplastic syndrome transformation Diseases 0.000 description 1
- 102100032970 Myogenin Human genes 0.000 description 1
- 108010056785 Myogenin Proteins 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 108700006416 NBPhox Proteins 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 102000005650 Notch Receptors Human genes 0.000 description 1
- 230000005913 Notch signaling pathway Effects 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108010028842 PAX2 Transcription Factor Proteins 0.000 description 1
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 1
- 101150081664 PAX6 gene Proteins 0.000 description 1
- 101150044101 PAX9 gene Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102100040851 Paired box protein Pax-1 Human genes 0.000 description 1
- 102100040852 Paired box protein Pax-2 Human genes 0.000 description 1
- 102100034901 Paired box protein Pax-9 Human genes 0.000 description 1
- 102100033829 Paired mesoderm homeobox protein 2 Human genes 0.000 description 1
- 102100026354 Paired mesoderm homeobox protein 2B Human genes 0.000 description 1
- 101710187408 Paired mesoderm homeobox protein 2B Proteins 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100033880 Prospero homeobox protein 1 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102100027753 Putative F-box/LRR-repeat protein 21 Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038272 Refractory anaemia with ringed sideroblasts Diseases 0.000 description 1
- 208000009527 Refractory anemia Diseases 0.000 description 1
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 description 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102000007508 Retinoblastoma-Binding Protein 4 Human genes 0.000 description 1
- 108010071034 Retinoblastoma-Binding Protein 4 Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 102100037205 Sal-like protein 2 Human genes 0.000 description 1
- 241001435139 Salia Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108700010572 Sine oculis homeobox homolog 3 Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 102100029853 T-box transcription factor TBX15 Human genes 0.000 description 1
- 101710141058 T-box transcription factor TBX15 Proteins 0.000 description 1
- 102100036773 T-box transcription factor TBX19 Human genes 0.000 description 1
- 101710141052 T-box transcription factor TBX19 Proteins 0.000 description 1
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 1
- 108010091885 T-box transcription factor TBX21 Proteins 0.000 description 1
- 102100036839 T-box transcription factor TBX22 Human genes 0.000 description 1
- 101710142753 T-box transcription factor TBX22 Proteins 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102100034737 Transcription factor LBX2 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 108010061610 Tva receptor Proteins 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 101150034003 Vax2 gene Proteins 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 238000010817 Wright-Giemsa staining Methods 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 102100028458 Zinc finger E-box-binding homeobox 2 Human genes 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000008777 canonical pathway Effects 0.000 description 1
- 208000001969 capillary hemangioma Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000032341 cell morphogenesis Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 210000001726 chromosome structure Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 230000000546 effect on cell death Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000037305 epidermis formation Effects 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 101150075707 esc gene Proteins 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 101150075618 foxd3 gene Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 108010027263 homeobox protein HOXA9 Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000009319 interchromosomal translocation Effects 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 101150000168 lhx9 gene Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 101150029117 meox2 gene Proteins 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 102000034272 protein filaments Human genes 0.000 description 1
- 108091005974 protein filaments Proteins 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000012256 transgenic experiment Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Definitions
- the invention relates generally to factors associated with the Wnt/ ⁇ -catenin signaling pathway and, more specifically, to interaction between transcription components of the pathway, including the SALL protein family and OCT4 and nanog, which are involved in the regulation of embryonic and cancer stem cells, including methods for the diagnosis and treatment of proliferative disorders by targeting such interaction. Further, SALL4 shutdown induces cancer stem cells to undergo apoptosis and cell-cycle arrest, which cells can be rescued by SALL4 downstream targets, including Bmi-1.
- ES cells derived from the inner cell mass (ICM) of the blastocyst are able to undergo self-renewing cell division and maintain their pluripotency over an indefinite period of time.
- ES cells can also differentiate into a variety of different cell types when cultured in vitro.
- the Wnt/ ⁇ -catenin signaling pathway has been associated with the self-renewal of normal human stem cells (HSCs) and the granulocyte-macrophage progenitors (GMPs) of chronic myeloid leukemia (CML).
- HSCs normal human stem cells
- GFPs granulocyte-macrophage progenitors
- CML chronic myeloid leukemia
- OCT4 has been identified as a key regulator for the formation of ICM during preimplantation development.
- OCT4 protein seems to plays a central role in maintaining the pluripotency of embryonic stem (ES) cells by regulating a wide range of genes.
- stem cells have been considered in the etiology of cancer.
- tumors might contain such cancer stems cells, i.e., rare cells that account for the growth of tumors.
- These rare cells with indefinite proliferative potential may account for the resistance observed for cancer cells in response to conventional therapeutic modalities.
- stem cells can be identified in adult tissues, where such cells arise from a specific tissue; e.g., hematopoietic cells.
- hematopoietic cells As the self renewal property
- MDS Myelodysplastic syndrome
- HSC hematopoietic stem cell
- AML acute myeloid leukemia
- LSCs leukemia stem cells
- downstream progenitors can acquire self-renewal capacity and give rise to leukemia.
- LSCs are not targeted specifically under current chemotherapy regimens yet such cells have been found to account for drug resistance and leukemia relapse.
- SALL gene family SALLl, SALL2, SALL3, and SALL4, were originally cloned on the basis of their DNA sequence homology to Drosophila spall (sal).
- Drosophila spalt is a homeotic gene essential for development of posterior head and anterior tail segments. It plays an important role in tracheal development, terminal differentiation of photoreceptors, and wing vein placement.
- the SALL gene family is associated with normal development, as well as tumorigenesis.
- SALL proteins belong to a group of C 2 H 2 zinc finger transcription factors characterized by multiple finger domains distributed over the entire protein.
- spalt is an activated downstream target of Wingless, a Wnt ortholog. It has been demonstrated that SALLl interacts with ⁇ -catenin by functioning as a coactivator, suggesting that the interaction between SALL and the Wnt/ ⁇ -catenin pathway is bidirectional.
- the present invention relates to SALL4, a human homolog to Drosophila spalt, which is a zinc finger transcriptional factor essential for development.
- SALL4 and its isoforms (SALL4A, SALL4B, and SALL4C) were cloned and sequenced.
- SALL4A, SALL4B, and SALL4C were cloned and sequenced.
- SALL4A, SALL4B, and SALL4C were cloned and sequenced.
- SALL4A, SALL4B, and SALL4C were cloned and sequenced.
- SALL4A, SALL4B, and SALL4C were cloned and sequenced.
- SALL4A, SALL4B, and SALL4C were cloned and sequenced.
- SALL4A, SALL4B, and SALL4C were cloned and sequenced.
- SALL4A, SALL4B, and SALL4C were
- CFU transgenic mouse marrow and colony-formation
- an antibody or antibody fragment which binds to a polypeptide that includes an amino acid sequence as set forth in SEQ ID NO: 13.
- a method of treating myelodysplastic syndrome (MDS) in a subject including administering a therapeutically effective amount of an antibody which binds to a polypeptide that includes an amino acid sequence as set forth in SEQ ID NO: 13 to the subject.
- MDS myelodysplastic syndrome
- a method of treating myelodysplastic syndrome (MDS) in a subject including administering to the subject a composition of a polynucleotide having a sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, a complement of SEQ ID NO: 1, a complement of SEQ ID NO: 3, a complement of SEQ ID NO: 5, and fragments thereof including at least 15 consecutive nucleotides of a polynucleotide encoding the amino acid sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO:6.
- MDS myelodysplastic syndrome
- a method of treating myelodysplastic syndrome (MDS) in a subject including administering to the subject a polypeptide composition having a sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 4 and/or SEQ ID NO: 6.
- the MDS is acute myeloid leukemia (AML).
- a method of diagnosing myelodysplastic syndrome (MDS) in a subject including, providing a biological sample from the subject, contacting the biological sample with a probe comprising a fragment of at least 15 consecutive nucleotides of a polynucleotide having a sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, a complement of SEQ ID NO: 1, a complement of SEQ ID NO: 3, or a complement of SEQ ID NO: 5 under hybridization conditions, and detecting the hybridization between the probe and the biological sample, where detecting of hybridization correlates with MDS.
- MDS myelodysplastic syndrome
- a method of diagnosing a myelodysplastic syndrome (MDS) in a subject including providing a biological sample from the subject, contacting the biological sample with an antibody which binds to a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, and detecting the binding of the antibody to the sample, where detecting binding correlates with MDS.
- MDS myelodysplastic syndrome
- a method for isolating leukemia stem cells including obtaining a sample of cells from a subject, sorting cells that express a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 13 from cells that do not express the amino acid sequence, and selecting, by a myeloid surface marker, leukemia stem cells from the sample of cells that express the polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 13.
- a transgenic animal having a human SALL4 gene where the animal is modified to expresses a sequence of a human SALL4 gene comprising nucleotides encoding an amino acid as set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO:
- the animal constitutively expresses the inserted SALL4 gene.
- a method of preparing a transgenic animal comprising a human SALL4 gene is disclosed, where the animal is modified to constitutively express a sequence of a human SALL4 gene comprising nucleotides encoding an amino acid as set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, including introducing into embryonic cells a nucleic acid
- l 3 56 077-000029 molecule a comprising a construct of human SALL4 gene comprising nucleotides encoding an amino acid as set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, generating a transgenic animal from the cells resulting from step the introduction of the construct, breeding the transgenic animal to obtain a transgenic animal homozygous for the human SALL4 gene, and detecting human SALL4 transcripts from tissue from the transgenic animal.
- a method of modulating the cellular expression of a polynucleotide encoding an amino acid sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 including introducing a double stranded RNA (dsRNA) which hybridizes to the polynucleotide, or an antisense RNA which hybridizes to the polynucleotide, or a fragment thereof, into a cell.
- dsRNA double stranded RNA
- a method of identifying a cell possessing pluripotent potential including contacting a cell isolated from an inner cell mass (ICM), a neoplastic tissue, or a tumor with an agent that detects the expression of a SALL family member protein, and determining whether a SALL family member protein is expressed in the cell, where determining the expression of the SALL family member protein positively correlates with induction of self- renewal in the cell, whereby such expression is indicative of pluripotency.
- ICM inner cell mass
- the SALL family member includes SALLl, SALL3, and SALL4.
- SALL4 is SALL4A or SALL4B.
- the agent is an antibody directed against the SALL family member protein or a nucleic acid which is complementary to a mRNA encoding the SALL family member protein.
- the SALL family member protein sequence includes SEQ ID NO: 2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:22, and SEQ ID NO:24.
- the nucleic acid is complementary to a sense strand of a nucleic acid sequence including SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5; SEQ ID NO:21, and SEQ ID NO:23.
- the cell is an embryonic stem (ES) cell, an embryonic carcinoma (EC) cell, an adult stem cell, or a cancer stem cell.
- the tissues is plasma or a biopsy sample from a subject.
- the subject is a human.
- a method of identifying an agent which modulates the effect of a SALL family member protein on OCT4 expression including co-transfecting a cell with a vector comprising a promoter-reporter construct, where the construct comprises an
- the promoter region comprises nucleic acid sequence as set forth in SEQ ID NO:26 and the expression reporter protein is luciferase.
- a method of diagnosing a neoplastic or proliferative disorder including contacting a cell of a subject with an agent that detects the expression of a SALL family member protein and determining whether a SALL family member protein is expressed in the cell, where determining the expression of the SALL family member protein positively correlates with induction of self-renewal in the cell, whereby such expression is indicative of neoplasia or proliferation.
- the agent is labeled and the determining step includes detection of the agent by exposing the subject to a device which images the location of the agent.
- the images are generated by magnetic resonance, X-rays, or radionuclide emission.
- a method of treating a neoplastic or proliferative disorder, where cells of a subject exhibit de-regulation of self-renewal including administering to the subject a pharmaceutical composition containing an agent which inhibits the expression of SALL4.
- kits for identifying a cell possessing pluripotent potential including an agent for detecting one or more SALL family member proteins, reagents and buffers to provide conditions sufficient for agent-cell interaction and labeling of the agent, instructions for labeling the detection reagent and for contacting the agent with the cell, and a container comprising the components.
- a method of detecting cells associated with progression of a proliferative disease or neoplastic cell formation including contacting the cells with an antibody directed against S ALL4, applying cells bound to the antibody to a surface delimited cavity comprising at least two apertures for ingress and egress of fluids and cells, and allowing cells and fluids to pass through the cavity, where antibody bound cells in a fluid mixture are detected by optical
- WliST ⁇ 2141 3 ⁇ 50.1 3 5 6()77-000029 detectors and where voltage is applied to the fluid whereby the voltage assorts the bound cells in one or more collectors.
- a method of diagnosing disorders of primordial cell origin in a subject including determining the expression of SALL4 in a tissue sample from the subject.
- the disorder is associated with a germ cell tumor (GCT).
- GCT germ cell tumor
- the GCT includes classic seminoma, spermatocyte seminoma, embryonal carcinoma, yolk sac tumor, or immature teratoma.
- the tissue sample comprises cells of testicular origin, including that substantially all mature testicular cell types present in the sample do not express SALL4. Further, the tissue sample may be obtained from a site which comprises cells that have metastasized from a GCT.
- a method of monitoring engraftment of transplanted stem cells in a subject including determining the level of expression of SALL4 in stem cells prior to transplantation into a subject, grafting the cells into the subject, and determining the level of expression of SALL4 in the grafted stem cells at time intervals post-transplantation, where a decrease in SALL4 expression over the time intervals correlates with differentiation of the stem cells, and where such differentiation is indicative of positive engraftment of cells in the subject.
- an increase in SALL4 expression over the time intervals correlates with repression of differentiation, and where such repression is indicative of negative engraftment of cells in the subject.
- the transplanted cell is transformed by a vector encoding an exogenous or endogenous gene product.
- a method for isolating stem cells from cord blood including obtaining umbilical cord cells (UBC) from a subject, sorting cells that express SALL4 from cells that do not express SALL4, where UBCs expressing SALL4 are indicative of isolated stem cells. Further, the method may include, optionally, selecting cells from the sorted cells that express SALL4 using one or more additional markers.
- UBC umbilical cord cells
- the one or more markers are selected from the group consisting of SSEA-I, SSEA-2, SSEA-4, TRA-I -60, TRA-I -81, CD34 4 , CD59 + , Thyl/CD90 + , CD38 lo/ ⁇ C-kif
- a method of treating a cancer of stem cell or progenitor cell origin including administrating to a subject in need thereof a composition containing an agent which reduces the expression level of SALL4.
- the agent is an oligonucleotide sequence selected from SEQ ID NO:30, SEQ ID NO:31; or SEQ ID NO:32.
- the composition comprises a methylation inhibitor, including but not limited to, 5' azacytidine, 5' aza-2-deoxycytidine, 1-B-D- arabinofuranosyl-5-azacytosine, or dihydroxy-5-azacytidine.
- the composition further comprises a proteasome inhibitor, including but not limited to,
- an isolated oligonucleotide is disclosed, which is selected from SEQ ID NO:30, SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33; or SEQ ID NO:34.
- Figures l(a-c) illustrate properties of the three SALL4 isoforms (SALL4A, SEQ ID NO: 1 [GenBank Ace. No.: AYl 72738]; SALL4B, SEQ ID NO: 3[GenBank Ace. No. AY170621]); and SALL4C, SEQ ID NO: 5 [GenBank Ace. No. AY170622].
- Alternative splicing generates two variant forms of S ALL4 niRNA.
- Figure 1 (a) S ALL4 A and S ALL4B vary in protein length and in the presence of different numbers of characteristic sal-like zinc finger domains.
- SALL4A (encoding 1,067 amino acids) contains eight zinc finger domains, while SALL4B (encoding 623 amino acids) has three zinc finger domains.
- SALL4C contains 276 amino acids and lacks the region corresponding to amino acids 43 to 820 of the full length SALL4A. Both variants have exons 1, 3, and 4, and SALL4A contains all exons from 1 to 4. However, SALL4B uses an alternative splice acceptor that results in deletion of the large 3' portion of exon 2.
- Figure l(b) shows the RT-PCR analysis of SALL4 variants in different tissues. Four exons of SALL4 and their potential coding structures are illustrated, with arrows indicating the primers used for PCR amplification of the SALL4 transcripts (A).
- Lysates from Cos-7 cells transiently expressing His-SALL4B (lane 1), His- S ALL4A (lane 2), or control vector (lane 8), or lysates from different human tissues were resolved by 10% SDS-PAGE gel, transferred onto a nitrocellulose membrane, and probed with the N-terminal SALL4 peptide antibody.
- Figure 2 demonstrates the expression of SALL4 in human primary AML and myeloid leukemia cell lines.
- Figures 3(a-e) show that SALL4B transgenic mice have an MDS-like/AML phenotype.
- Figure 3 (a) illustrates the generation of SALL4B transgenic mice: CMV/SALL4B transgenic construct and PCR analysis of transgenic line 507.
- A Schematic diagram of transgenic construct. The approximately 1.8-kb cDNA of SALL4B was subcloned into a pCEP4 vector, and the CMV/SALL4 construct was excited by digestion with Sail.
- B Tissue distribution of SALL4B in transgenic mice. The location of primers used for RT-PCR amplification is indicated by arrows in part A.
- FIG. 3(b) shows the flow cytometric analysis of AML in SALL4B transgenic mice. AML cells were positive for CD45, c-kit, Gr-I, and Mac-1 ; negative for B220, CD3, and Terl 19.
- Figure 3(c) illustrates the comparison between bone marrow of SALL4B transgenic and control mice.
- SALL4B transgenic mouse bone marrow showed increased cellularity, myeloid population (Gr-I /Mac-1 double positive), immature population (c-kit positive), and apoptosis (Annexin V positive, PI negative), compared with control WT mice.
- Figure 3(d) shows that there are an increased number of immature cells and apoptosis in CFUs from SALL4B transgenic mice.
- apoptotic cells B, C, and D, double red arrows
- Figures 4(a-c) demonstrate the interaction between SALL4 and the Wnt/ ⁇ -catenin signaling pathway.
- Figure 4(a) shows that both SALL4A and SALL4B can interact with ⁇ - catenin.
- Nuclear extracts (lysates) prepared from Cos-7 cells were transiently transfected with HA-SALL4A or HA-SALL4B.
- A) Anti-HA antibody recognized both SALL4A (165 kDa) and SALL4B (95 kDa).
- B ⁇ -Catenin was detected in the lysates.
- WEST ⁇ 214130 5 0.1 3 5 6077-000029 shows the activation of the Wnt/ ⁇ -catenin signaling pathway by both SALL4A and SALL4B.
- NIH3T3 cells were transfected with 1.0 ⁇ g of either SALL4A or SALL4B plasmid and TOPflash reporter plasmid (Upstate USA, Chicago, IL). After 24-h stimulation with Wntl or the mock, luciferase activity was measured.
- Figure 4(c) illustrates a working hypothesis.
- SALL4 is expressed in human stem cells/progenitors but is absent in mature hematopoietic cells during normal hematopoiesis.
- Figure 5 illustrates dose-dependent effect of SALL4B on the OCT4 promoter.
- 0.3 ⁇ g of OCT4-Luc construct (PMOct4) was cotransfected with 0.1 ⁇ g of renilla plasmid and increasing amounts (0-1.0 ⁇ g) of SALL4B or pcDNA3 vector control.
- Figure 6 demonstrates the effect of OCT4 on SALL gene family member promoters.
- SALL-Luc promoter construct i.e., pSALLl, pSALL3, and pSALL4
- OCT4 or pcDNA3 vector control was cotransfected with 0.9 ⁇ g of OCT4 or pcDNA3 vector control in HEK-293 cells. After 24 hr post- transfection, luciferase activity was evaluated for each group.
- Figure 7 shows the effect of SALL4 isoforms A and B on SALL4 promoter activity.
- 0.3 ⁇ g of SALL4-Luc was cotransfected with 0.1 ⁇ g of either SALL4A or SALL4B expressing plasmid in different cell lines (HEK-293 or COS-7); pcDNA3 vector was used as the control. Luciferase activity was normalized for renilla reporter activity. The values represent the mean ⁇ s.e. of three experiments.
- Figure 8 demonstrates the dose dependent effect of SALL4A on SALL4 promoter activity.
- 0.3 ⁇ g of the SALL4-Luc was co-transfected with 0.1 ⁇ g of renilla plasmid and increasing ratios of the SALL4A construct and the control pcDNA3 vector.
- the Luciferase activity is normalized for the Renilla reporter activity.
- Figure 9 shows the effect of SALL4 on SALLl and SALL3 promoter activity.
- Each (0.3 ⁇ g) SALL-Luc promoter construct was transiently co-transfected with 0.9 ⁇ g of SALL4A plasmid or pcDNA3 vector (control) in HEK-293 cells.
- FIG. 10 shows the effect of OCT4 on the S ALL4 promoter in the presence of excess SALL4A.
- 0.25 ⁇ g of SALL4-Luc construct (pSALL4) was transiently co-transfected with equal
- WESTO 1413O 5 0.1 3 5 6077-000029 amounts (0.5 ⁇ g) of SALL4A and OCT4 plasmid in the HEK-293 cells.
- pcDNA3 was used as a control.
- Figure 11 shows the effect of OCT4 on other SALL member promoters in the presence of SALL4.
- HEK-293 cells seeded in a 24 well plate were transiently co-transfected with a different SALL member promoter reporter (pSALLl or pSALL3) and OCT4 plasmid and/or SALL4A construct.
- pSALLl or pSALL3 SALL member promoter reporter
- Figure 12 shows the effect of self promoter interaction on promoter activity for other SALL protein family members.
- HEK-293 cells were seeded on a 24 well plate and transiently transfected or co-transfected with 0.3 ⁇ g SALLl -Luc reporter construct with various amounts of SALLl plasmid (0.45 and 0.9 ⁇ g) SIXl, previously found to activate SALLl promoter, was used as a positive control.
- Luciferase activity was normalized for renilla reporter activity.
- FIG. 13 shows that SALL4 binds genes to Oct4 and Nanog as well as their networks.
- A Comparison with published data shows that SALL4 binds genes common to Oct4 and Nanog binding locations.
- B and
- C Western blots for SALL4, Oct4 and Nanog. These suggests that these three proteins work together to maintain pluripotency in ES cells.
- FIG. 14 shows that SALL4 functions to maintain pluripotency.
- A Genes identified as pluripotency markers for each of the four cell lineages bound in the ChIP-chip.
- B Using real-time PCR we analyzed mRNA levels for various markers for pluripotency after SALL4 shutdown. Levels of mRNA increased for endoderm, ectoderm and trophectoderm markers, indicating that SALL4 represses differentiation into these cell lineages.
- FIG 15 shows that SALL4 binds to downstream targets of PRCl and PRC2.
- A To better illustrate the regulatory mechanisms of PRCl and PRC2 we compared the transcription factors bound by SALL4, Rnf2 and Suzl2. For example, Suzl2 only has two unique transcription factors and shares others with Rnf2, SALL4, or both SALL4 and Rnf2.
- B Representation of developmentally important genes bound by S ALL4.
- HOX homeobox protein
- PAX paired box
- DLX distal-less homeobox
- SIX serine oculis homeobox homologue
- RBX reactive homeobox
- H6 H6 homeobox
- OBX oocyte specific homeobox
- LHX LIM homeobox
- FBX F-box
- FOX forkhead box
- T-box T-box
- Figure 16 shows that SALL4 regulates methylation events associated with H3K4 and H3K27.
- FIG 17 shows that SALL4 binds to signaling pathways vital to cell fate decisions.
- SALL4 binds gene promoters belonging to various pathways and we suggest that it plays a regulatory role in these pathways.
- B Quantitative representation of pathways bound by SALL4. The values reflect genes bound directly in the pathway or as downstream targets of the pathway.
- C Using the Wnt/B-catenin signaling pathway, we show the effects of SALL4 shutdown on the canonical pathway (green is down-regulation, red is up-regulation of expression).
- Figure 18 demonstrates that expansion of HSC and HPC were correlated with disease progression in S ALL4B transgenic mice. Increased c-kit positive HSCs/HPCs in SALL4B transgenic mice are contrasted with WT control mice where c-kit positive cells are approximately 6.5+2.5% of the total bone marrow cells. This population was increased in pre-leukemic (MDS) SALL4B transgenic mice and became even more prominent in leukemic SALL4B bone marrow.
- MDS pre-leukemic
- FIG. 19 shows LSCs in SALL4B transgenic mice.
- Whole bone marrows from SALL4B transgenic mice were sorted to HSCs, CMPs (common myeloid progenitors), GMPs (granulocyte/macrophage progenitors), and MEPs (megakryocyte/erythroid progenitors) and then transplanted into the primary NOD-SCID recipients.
- CMPs common myeloid progenitors
- GMPs granulocyte/macrophage progenitors
- MEPs megakryocyte/erythroid progenitors
- Representative FACS-staining profiles of HSCs and HPCs from bone marrows of WT NOD-SCID mice, primary leukemic NOD-SCID recipients, and secondary leukemic NOD-SCID mice showed that GMP cells were substantially increased during leukemic transplantation.
- the increase of HSCs in leukemic SALL4B transgenic mice and leukemic NOD-SCID recipients were variable.
- Figure 20 shows caspase-3 activity, cell cycle and cellular DNA synthesis in SALL4 suppressed-NB4.
- a and D NB4 transduced with control retrovirus.
- B and E NB4 cells transduced with SALL4 siRNA retroviruses;
- C and F restoration of Bmi-1 by ectopically expressing Bmi-1.
- Evidence showing that siRNA shutdown of SALL4 induces apoptosis in NB4 cells A and B).
- SALL4 shutdown NB4 cells can be rescued from apoptosis (C).
- SALL4 knockdown apoptosis
- WESTV21413050.1 3 5 6077-0000 2 9 induces cell cycle arrest and increased DNA synthesis (D and E ).
- SALL4 shutdown cells can be rescued from cell cycle arrested and DNA synthesis (F).
- Two siRNA retroviral constructs that target different regions of the SALL4 are made, and their ability to reduce SALU mRNA in NB4 cells are confirmed by Q-RT-PCR. In both SALL4 siRNA constructs, down-regulation of SALL4 also significantly reduced Bmi-1 levels.
- Figure 21 demonstrates that treatment with 5-azacytidine (5AC) significantly suppresses SALL4 and its downstream target, Bmi-1, but increases expression of the tumor suppressor gene, pl6INK4a.
- 5AC 5-azacytidine
- marked knockdown of Bmi-1 and SALL4 expression were observed in a dose-dependent manner of about 50-95% and 64-98%, respectively.
- pl6 INK4A mRNA expression significantly increased by 5-6 folds compared to the untreated control.
- Figure 22 shows dose-dependent activation of Bmi-1 promoter by SALL4 in HEK-293 cells.
- 0.25 ⁇ g of the Bmi-1 -Luc construct was co-transfected with 0.04 ⁇ g of Renilla Luciferase plasmid and increasing ratios of either the SALL4A or SALL4B expressing construct; pcDNA3 was used as the control.
- Data represent the mean of three individual experiments.
- Figure 23 shows the mapping of the SALL4 functional site within the Bmi-1 promoter region by a luciferase reporter gene assay.
- a luciferase reporter gene assay In HEK-293 cells, 0.3 ⁇ g of different length Bmi-1 - Luc constructs were co-transfected with 0.04 ⁇ g of Renilla Luciferase plasmid and 0.9 ⁇ g of either SALL4A or SALL4B plasmid.
- the A P1254 and ⁇ P683 refer to Bmi-1 mutant promoter constructs, -1254 or -683, in which the -270 to -168 sequence was deleted.
- Figure 24 shows that SALL4 specifically binds to the endogenous mouse Bmi-1 promoter (-450 to 1+) using ChIP assays.
- A Schematic representation of the primer sets specific for Bmi- 1 promoter.
- B Chip assays were performed by using an antibody against HA (lane +) or preimmune sera (lane -); enriched chromatin was analyzed by PCR with primers as shown in A.
- C Relative enrichment of Bmi-1 promoter regions in 32D cells that were
- FIG. 25 shows the effects of endogenous Bmi-1 expression levels.
- siRNA mediated SALL4 suppression in leukemia cells Three siRNA oligonucleotides, targeting the SALL4 gene at position 890, 1682, and 1705, respectively, were cloned into a pSUPER retrovirus vector; PT67 packaging cells were transfected and HL-60 cells were infected with the virus collected after 48 hr of infection. Stable infected cells were collected under G418 selection. Total RNA was extracted by Trizol, RT PCR was performed, and the relative amount of target gene niRNA was analyzed. The SALL4/GAPDH ratio in noninfected cells was set at 1; values are the mean of duplicate reactions.
- Figure 26 demonstrates that mRNA expression of Bmi-1 and SALL4 in human AML blast samples showed a strong correlation between Bmi-1 and SALL4 expression.
- Twelve randomly selected blastic AML samples were analyzed using RT PCR to enhanced expression quantify relative mRNA expression of Bmi-1 and SALL4 genes.
- Ten out of 12 AML samples showed significant Bmi-1 gene amplification ranging from 1.10- to 22.32-fold increase relative to the averaged normal controls (Normal).
- the same 10 of 12 AML samples also showed elevated SALL4 gene expression amplification, ranging from a 3.93- to 653.03-fold increase relative to the averaged normal controls.
- the Log 10 scale represents the relative quantification of genes of interest. Using data for the 12 AML samples, we preformed a statistical analysis and determined the correlation coefficient to be 0.703 with a p-value of 0.0159.
- Figure 27 shows that SALL4 specifically binds to the endogenous mouse Bmi-1 promoter (-450 to 1+) resulting in histone 3 lysine 4 and lysine 79 methylation using chromatin immunoprecipitation (ChIP) assays. Enriched chromatin was analyzed by PCR with the primers shown in Figure 3 A.
- Figure 6 A and 6B are distributions of the histone 3 trimethylation levels of H3-K4 and H3-K79 on the Bmi-1 promoter regions, respectively, in 32D cells that were transfccted with SALL4A tagged with HA or control DNA, pcDNA3.
- ChIP assays were performed using histone H3-K4 trimethylation antibody (A) and histone H3-K79 methylation antibody (B). Amplicons were quantitated by Q-PCR. Experiments were repeated three times with similar results.
- FIG. 28 shows that SALL4 expression is decreased during NTERA2 cell differentiation.
- Figure 29 shows the effects of endogenous Bmi-1 expression levels and cell differentiation by SALL4 knockdown are shown.
- Two siRNA oligonucleotides (#7410, #7412) targeting different regions of the SALL4 gene are transfected in PT67 packaging cells.
- NTERA2 cells are infected with the virus collected 48 hours post-transfection. Total RNA is extracted and Q-RT-PCR is performed to analyze the relative amount of target gene mRNA.
- the S ALL4/GAPDH ratio in noninfected cells is set at one. Values are the mean of duplicates, and bars indicate standard deviation.
- Figure 30 shows representative FACS data of caspase-3 activity in NTERA2 and SALL4-deleted NTERA2 cells.
- Evidence showing that siRNA shutdown of SALL4 induces apoptosis in NTERA2 cells A and B.
- Bmi-1 SALL4 shutdown cells can be rescued from apoptosis (C).
- Bmi-1 has little effect on caspase-3 activity in WT NTERA2 cells (D).
- Figure 31 shows Monitored cell-cycle changes and cellular DNA synthesis in SALL4- depleted NTERA2 and NTERA2 cells by both BrdU incorporation assay and FACS.
- SALL4 knockdown induces cell cycle arrest and increased DNA synthesis (A and B).
- Bmi-1 By ectopically expressing Bmi-1, SALL4 shutdown cells can be rescued from cell cycle arrested and DNA synthesis (C) but a control vector does not (data not shown), overexpression of Bmi-1 has little effect on cell cycle arrest and increased DNA synthesis in wild type NTERA2 cells (D).
- references to “a nucleic acid” includes one or more nucleic acids, and/or compositions of the type described herein which will become apparent to those persons skilled in the art upon reading this disclosure and so forth.
- SALL4 is a member of a family Of C 2 H 2 zinc-finger transcription factors. SALL4 was originally cloned based on its homology to Drosophila splat. In Drosophila, sal is a homeotic gene and essential in the development of posterior head and anterior tail segments. In humans, an autosomal-dominant mutation is associated with Okihiro syndrome (also called Duane-radial ray syndrome), which causes defects in multiple organ systems. Mutations in the SALL4 gene severely hinder development in many animal models.
- SALL4 seems to regulate embryonic stem cell (ESC) pluripotency through interaction with major regulatory proteins including Oct4 and Bmi-I.
- Bmi-1 is a member of the polycomb group (PcG) of proteins initially identified in Drosophila as a repressor of homeotic genes.
- the polycomb gene Bmi-1 plays an essential role in regulating adult, self-renewing, hematopoietic stem cells (HSCs) and leukemia stem cells (LSCs).
- HSCs hematopoietic stem cells
- LSCs leukemia stem cells
- Bmi-1 is expressed highly in purified HSCs, and its expression declines with differentiation.
- Knockout of the Bmi-1 gene in mice results in a progressive loss of all hematopoietic lineages. This loss results from the inability of the Bmi-1 (-/-) stem cells to self- renew.
- Bmi-1 (-/-) cells display altered expression of the cell cycle inhibitor genes pl6INK4a and pi 9ARF.
- the expression of Bmi-1 appears to be important in accumulation of leukemic cells.
- inhibiting self-renewal in tumor stem cells after deleting Bmi-1 can prevent leukemic recurrence.
- Bmi-1 expression has been used as an important marker for predicting the development of MDS and disease progression to AML.
- Embryonic stem cells have become the focus of scientific research due to their regenerative capacity and potential uses in disease therapies. Stem cells have been shown to give rise to all three germ layers (ectoderm, mesoderm, and endoderm) during embryogenesis emphasizing their pluripotent potential. Cellular machinery that governs ES cells is vital to their
- WEST ⁇ 21413050.1 356077-000029 function because it regulates the differentiation signals and pluripotency maintenance signals necessary for proper development.
- ES cells are derived from the inner cell mass (ICM) of the developing embryo. During this critical time, ES cell pluripotency is regulated in part by Oct4, Sox2, and Nanog as well as through the two Polycomb Repressive Complexes (PRCs): PRCl and PRC2.
- SALL4 may play a vital role in governing ES cells proliferation and pluripotency. For example, embryonic endoderm ES cells cannot be established from SALL4 deficient blastocyts. SALL4 is expressed by cells of the early embryo and germ cells, exhibiting a similar expression pattern to that of both Oct4 and Sox2. This suggests that SALL4 may be a regulator of a network of genes implicated in maintaining ES cell pluripotency.
- Homeobox and homeotic genes play important roles in normal development. Some homeobox genes, such as Hox and Pax, also function as oncogenes or as tumor suppressors in tumorigenesis or leukemogenesis. The important role of S ALL4, a homeotic gene and a transcriptional factor, in human development was recognized because heterozygous SALL4 mutations lead to Duane Radial Ray syndrome. In a related aspect, SALL4's oncogenic role in leukemogenesis is described herein.
- the present disclosure identifies two SALL4 isoforms, SALL4A and SALL4B.
- the disclosure provides an analysis of SALL4 nucleic acids and proteins as tools for diagnosing and treating patients having proliferation disorders such as hematologic malignancies and other tumors involving constitutive expression of SALL4 nucleic acid and protein.
- SALL4 serves as a malignant stem cell marker for diagnosis and treatment of cancers.
- SALL4 isoforms are expressed in the CD34+ HSC/HPC population and rapidly turned off (SALL4B) or down-regulated (SALL4A) in normal human bone marrow and peripheral blood.
- the leukemogenic potential of constitutive expression of S ALL4 in vivo was directly tested via generation of S ALL4B transgenic mice.
- Such transgenic mice exhibit dysregulated hematopoiesis, much like that of human MDS, and exhibited AML that was transplantable.
- the MDS-like features in these SALL4B transgenic mice do not require cooperating mutations and are observed as early as 2
- chromosomal translocations characterize many leukemias, which can result from a breakdown in the normal process of immunoglobulin or T-cell receptor gene rearrangement, causing inter-chromosomal translocations rather than normal intra- chromosomal rearrangement.
- the flow of genetic information from genes at chromosomal translocation breakpoints to proteins has several points which therapeutic reagents could intervene.
- Sequence specific binding elements that exploit zinc-finger binding protein domains can be used to create de novo sequence specific binding elements that could act as gene switches which can target chromosomal fusion junctions to turn off expression of aberrant gene fusion products.
- S ALL4 can be used as a component of a fusion protein which targets chromosomal fusion junctions as a gene switch to modulate the expression of gene fusion products.
- Production of recombinant fusion protein is well known in the art (see, e.g., Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd PId.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. (1989).
- SALL4 proteins and/or nucleic acids are detected for diagnosing subpopulations of lymphomas and leukemias or other types of cancers.
- the detection of the SALL4 proteins and nucleic acids can be used to identify a subject, including, but not limited to, a human subject, at risk for developing/acquiring a proliferative disease.
- SALL4 can serve as a therapeutic target, where blocking SALL4 function can inhibit tumor development and progression.
- the oncogene SALL4 plays an important role in normal hematopoiesis and leukemogenesis.
- SALL4B transgenic mice exhibit MDS-like phenotype with subsequently AML transformation that is transplantable. Few animal models are currently available for the study of human MDS.
- the SALL4B transgenic mice that were generated by the methods described herein provide a suitable animal model for understanding and treating human MDS and its subsequent transformation to AML.
- the interaction between SALL4 and the Wnt/ ⁇ -catenin signaling pathway not only provides a plausible mechanism for S ALL4 involvement in leukemogenesis but also advances the understanding of the activation of the Wnt/ ⁇ -catenin signaling pathway in CML blastic transformation.
- SALL4 isoforms and their constitutive expression in all human AML were examined.
- the disclosure demonstrates that constitutive expression of SALL4 in mice is sufficient to induce MDS-like symptoms and transformation to AML that is transplantable.
- the disclosure also demonstrates that SALL4 is able to bind ⁇ -catenin and activate the Wnt/ ⁇ -catenin signaling pathway. SALL4 and ⁇ -catenin share similar expression patterns at different phases of CML.
- an isolated polynucleotide comprising a sequence encoding an amino acid sequence as set forth in SEQ ID NO: 2 (GenBank Ace. No. AAO44950), SEQ ID NO: 4 (GenBank Ace. No. AAO16566), or SEQ ID NO: 6 (GenBank Ace. No. AAO16567) is provided.
- sequences comprise a nucleic acid sequence as set forth in SEQ ID NO: 1 (GenBank Ace. No. AY172738), SEQ ID NO: 3 (GenBank Ace. No. AY170621), SEQ ID NO: 5 (GenBank Ace. No. AY170622), or complements thereof.
- a vector comprising such polynucleotides are also disclosed, including, but not limited to, expression vectors which are operably linked to a regulatory sequence which directs the expression of the polynucleotide in a host cell.
- an isolated polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 is disclosed.
- a method of treating a myelodysplastic syndrome (MDS) in an individual including administering such a polypeptide is provided.
- antibodies or binding fragments thereof which bind to such a polypeptide are also disclosed.
- Antibodies that are used in the methods disclosed include antibodies that specifically bind polypeptides comprising SALL4, or their isoforms as set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6.
- a fragment of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 is used to generate such antibodies.
- such a fragment consists essentially of SEQ ID NO: 13.
- a method of identifying a cell possessing pluripotent potential including contacting a cell isolated from an inner cell mass (ICM), a neoplastic tissue, or a tumor with an agent that detects the expression of a SALL family member protein, and determining whether a SALL family member protein is expressed in the cell, where determining the expression of the SALL family member protein positively correlates with induction of self- renewal in the cell, whereby such expression is indicative of pluripotency.
- ICM inner cell mass
- the SALL family member includes SALLl, SALL3, and SALL4.
- SALL4 is SALL4A or SALL4B.
- the agent is an antibody directed against the SALL family member protein or a nucleic acid which is complementary to a mRNA encoding the SALL family member protein.
- the SALL family member protein sequence includes SEQ
- the nucleic acid is complementary to a sense strand of a nucleic acid sequence including SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5; SEQ ID NO:21, and SEQ ID NO:23.
- the cell is an embryonic stem (ES) cell, an embryonic carcinoma (EC) cell, an adult stem cell, or a cancer stem cell.
- the tissues is plasma or a biopsy sample from a subject.
- the subject is a human.
- primary cell means an originally or earliest formed cell in the growth of an individual or organ.
- progenitor cell means a parent cell that gives rise to a distinct cell lineage by a series of cell divisions.
- pluripotent potential means the ability of a cell to renew itself by mitosis.
- neoplasm means new and abnormal growth of tissue, which may be benign or cancerous.
- a fusion protein comprising SEQ ID NO: 13 and an adjuvant, for generating an immunogenic response against SEQ ID NO: 2, SEQ ID NO: 4, and/or SEQ ID NO: 6, would consist essentially of SEQ ID NO: 13.
- Antibodies are well-known in the art and discussed, for example, in U.S. Pat. No. 6,391,589.
- Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding
- immunoglobulin molecules refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen.
- the immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2) or subclass of immunoglobulin molecule.
- Antibodies of the invention include antibody fragments that include, but are not limited to, Fab, Fab' and F(ab')2, Fd, single-chain Fvs (scFv), single-chain antibodies, disulf ⁇ de- linked Fvs (sdFv) and fragments comprising either a VL or VH domain.
- Antigen-binding antibody fragments, including single-chain antibodies may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CHl, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CHl, CH2, and CID domains.
- the antibodies of the invention may be from any animal origin including birds and mammals.
- the antibodies are human, murine (e.g., mouse and rat), donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken. Further, such antibodies may be humanized versions of animal antibodies (see, e.g., U.S. Pat. Nos.: 6,949,245).
- the antibodies of the invention may be monospecific, bispecif ⁇ c, trispecific or of greater multispecificity.
- the antibodies of the invention may be generated by any suitable method known in the art.
- Polyclonal antibodies to an antigen-of-interest can be produced by various procedures well known in the art.
- a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen.
- adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum. Such adjuvants are also well known in the art. Further, antibodies and antibody-like binding proteins may be made by phage display (see, e.g., Smith and Petrenko, Chem Rev (1997) 97(2):391-410).
- Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof.
- monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example; in Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: Monoclonal Antibodies and T-CeIl Hybridomas 563-681 (Elsevier, N. Y., 1981) (said references incorporated by reference in their entireties).
- the term “monoclonal antibody” as used herein is not limited to antibodies produced through hybridoma technology.
- the term “monoclonal antibody” refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.
- a method for isolating leukemia stem cells using such antibodies including obtaining a sample of cells from a subject, sorting cells that express an amino acid sequence as set forth in SEQ ID NO: 13 from cells that do not express the amino acid sequence, and selecting, by a myeloid surface marker, leukemia stem cells from the sample of cells that express the amino acid sequence as set forth in SEQ ID NO: 13.
- the step of sorting includes sorting by fluorescent activated cell sorting and/or magnetic bead sorting.
- the marker is CD34, c-kit, Gr-I, Mac-1, MPO, and/or nonspecific esterase.
- the marker is SSEA-I, SSEA-2, SSEA-4, TRA-1-60, TRA-1-81, CD34 + , CD59 + , Thyl/CD90 + , CD38 lo/ ⁇ C-kif /l0 , Hn " , SH2, vimentin, periodic acid Schiff activity (PAS), FLKl, BAP, or acid phosphatase.
- markers can include those as set forth in Table 1.
- Smooth muscle cell- Smooth muscle Identifies smooth muscle cells in the wall of blood vessels specific myosin heavy chain Vascular endothelial Smooth muscle Identifies smooth muscle cells in the wall of blood vessels cell cadherin
- Bone-specific Osteoblast Enzyme expressed in osteoblast, activity indicates bone alkaline formation phosphatase (BAP) Hydroxyapatite Osteoblast Minerlized bone matrix that provides structural integrity; marker of bone formation
- Osteocalcin Osteoblast Mineral-binding protein uniquely synthesized by osteoblast; marker of bone formation
- BMPR bone Mesenchymal stem and Important for the differentiation of committed morphogenetic progenitor cells mesenchymal cell types from mesenchymal stem and protein receptor progenitor cells; BMPR identifies early mesenchymal (BMPR) lineages (stem and progenitor cells) CD4 and CD8 White blood cell (WBC) Cell-surface protein markers specific for mature T lymphocyte (WBC subtype)
- BMPR early mesenchymal
- WBC White blood cell
- CD34 Hematopoietic stem Cell-surface protein on bone marrow cell, indicative of a cell (HSC), satellite, HSC and endothelial progenitor; CD34 also identifies endothelial progenitor muscle satellite, a muscle stem cell
- CD34 + Scal + Lm Mesencyhmal stem cell Identifies MSCs, which can differentiate into adipocyte, profile (MSC) osteocyte, chondrocyte, and myocyte
- CD38 Absent on HSC Cell-surface molecule that identifies WBC lineages Selection of CD34 + /CD38 cells allows for purification of
- CD44 Mesenchymal A type of cell-adhesion molecule used to identify specific types of mesenchymal cells
- Colony-forming unit HSC, MSC progenitor CFU assay detects the ability of a single stem cell or (CFU) progenitor cell to give rise to one or more cell lineages, such as red blood cell (RBC) and/or white blood cell (WBC) lineages
- Fibroblast colony- Bone marrow fibroblast An individual bone marrow cell that has given rise to a forming unit (CFU- colony of multipotent fibroblastic cells, such identified cells F) are precursors of differentiated mesenchymal lineages Hoechst dye Absent on HSC Fluorescent dye that binds DNA, HSC extrudes the dye and stains lightly compared with other cell types
- Lm Leukocyte common WBC Cell-surface protein on WBC progenitor antigen
- Mac-1 WBC Cell-surface protein specific for mature granulocyte and macrophage WBC subtypes
- Muc-18 (CD146) Bone marrow Cell-surface protein (immunoglobulin superfamily) found on fibroblasts, endothelial bone marrow fibroblasts, which may be important in hematopoiesis, a subpopulation of Muc-18+ cells are mesenchymal precursors
- HSC Stem cell antigen HSC, MSC Cell-surface protein on bone marrow (BM) cell, indicative of (Sca-1) HSC and MSC Bone Marrow and Blood cont Stro-1 antigen Stromal Cell-surface glycoprotein on subsets of bone marrow (mesenchymal) stromal (mesenchymal) cells; selection of Stro-1+ cells precursor cells, assists in isolating mesenchymal precursor cells, which are hematopoietic cells multipotent cells that give rise to adipocytes, osteocytes, smooth myocytes, fibroblasts, chondrocytes, and blood cells
- Thy-1 HSC MSC Cell-surface protein
- negative or low detection is suggestive of HSC Cartilage
- Adipocyte lipid- Adipocyte Lipid-binding protein located specifically in adipocyte binding protein Adipocyte lipid- Adipocyte Lipid-binding protein located specifically in adipocyte binding protein (ALBP)
- Adipocyte Transport molecule located specifically in adipocyte transporter Fatty acid Adipocyte Transport molecule located specifically in adipocyte transporter (FAT)
- Liver Albumin Hepatocyte Principal protein produced by the liver indicates functioning of maturing and fully differentiated hepatocytes B-I integrin Hepatocyte Cell-adhesion molecule important in cell-cell interactions; marker expressed during development of liver Nervous System
- CD133 Neural stem cell HSC Cell-surface protein that identifies neural stem cells, which give rise to neurons and glial cells
- Glial fibrillary acidic Astrocyte Protein specifically produced by astrocyte protein (GFAP)
- Microtubule- Neuron Dendrite-specific MAP protein found specifically in dendritic asso ⁇ ated prote ⁇ n-2 branching of neuron
- Neurofilament NF
- Important structural protein for neuron identifies differentiated neuron
- ES ES cells indicates presence of early neurons and glia
- Noggin Neuron A neuron-specific gene expressed during the development of neurons
- Synaptophysm Neuronal protein located in synapses indicates connections between neurons
- Ta u Neuron Type of MAP helps maintain structure of the axon Pancreas
- Pancreatic epithelium CK19 identifies specific pancreatic epithelial cells that are
- pancreatic Pancreatic islet Expressed by gamma-islet cell of pancreas polypeptide
- ES Alkaline Embryonic stem
- PSC pluripotent stem cell
- Alpha-fetoprotein Endoderm Protein expressed during development of primitive (AFP) endoderm reflects endodermal differentiation
- GATA-4 gene Endoderm Expression increases as ES differentiates into endoderm GCTM-2 ES, EC Antibody to a specific extracellular-matrix molecule that is synthesized by undifferentiated PSCs
- HNF-4 Hepatocyte nuclear Endoderm Transcription factor expressed early in endoderm formation factor-4 (HNF-4)
- Stage-specific ES EC Glycoprotein specifically expressed in early embryonic embryonic antigen- development and by undifferentiated PSCs 3 (SSEA-3)
- Stage-specific ES EC Glycoprotein specifically expressed in early embryonic embryonic antigen- development and by undifferentiated PSCs 4 (SSEA-4)
- Stem cell factor ES EC, HSC, MSC Membrane protein that enhances proliferation of ES and EC (SCF or c-Kit cells, hematopoietic stem cell (HSCs), and mesenchymal ligand) stem cells (MSCs); binds the receptor c-Kit Telomerase ES, EC An enzyme uniquely associated with immortal cell lines; useful for identifying undifferentiated PSCs
- TRA-1-60 ES EC Antibody to a specific extracellular matrix molecule is synthesized by undifferentiated PSCs TRA-1-81 ES, EC Antibody to a specific extracellular matrix molecule normally synthesized by undifferentiated PSCs Vimentin Ectoderm, neural and Intermediate filaments within cells; characteristic of pancreatic progenitor primitive neuroectoderm formation
- MyoD and Pax7 Myoblast myocyte Transcription factors that direct differentiation of myoblasts into mature myocytes Myogenin and MR4 Skeletal myocyte Secondary transcription factors required for differentiation of myoblasts from muscle stem cells Myosin heavy chain Cardiomyocyte A component of structural and contractile protein found in cardiomyocyte Myosin light chain Skeletal myocyte A component of structural and contractile protein found in skeletal myocyte
- kits for identifying a cell possessing pluripotent potential including an agent for detecting one or more SALL family member protein markers, reagents and buffers to provide conditions sufficient for agent-cell interaction and labeling of the agent, instructions for labeling the detection reagent and for contacting the agent with the cell, and a container comprising the components.
- cells are obtained from the bone marrow of a non-fetal animal, including, but not limited to, human cells. Fetal cells may also be used.
- Cell sorting may be by any method known in the art to sort cells, including sorting by fluorescent activated cell sorting (FACS) (see, e.g., Baumgarth and Roederer, J Immunol Methods (2000) 243:77-97) and Magnetic bead cell sorting (MACS).
- FACS fluorescent activated cell sorting
- MACS Magnetic bead cell sorting
- the conventional MACS procedure is described by Miltenyi et al., "High Gradient Magnetic Cell Separation with MACS," Cytometry 1 1 :231-238 (1990).
- MACS fluorescent activated cell sorting
- MACS Magnetic bead cell sorting
- an antibody directed against SALL4 is used in cell sorting to isolate embryonic stem cells, adult stem cells and/or cancer stem cells.
- an antibody directed against SALL4 is used in flow cytometry analysis to detect cells expressing SALL4, where such cells are associated with proliferative disease progression or neoplastic cell formation.
- SALL4 is SALL4A or SALL4B.
- MDS Myelodysplasia Syndrome
- HSC hematopoietic stem cell
- AML Acute Myeloid Leukemia
- LSCs leukemic stem cells
- blast cells leukemia cells
- SALL4 is a critical stem gene that modulates stem cell pluripotency.
- SALL4 knockdown results in massive apoptosis associated with reduction of Bmi-1.
- the SALL4-inducQd apoptosis can be fully rescued by restoring Bmi-1 to a normal level. While not being bound by theory, it seems that SALL4-induced apoptosis involves through regulation of Bmi-1.
- the present invention demonstrates that overexpression of SALL4 in mice transforms HSCs/HPCs into LSCs with up-regulation of Bmi-1. Moreover, SALL4 is able to bind to the Bmi-1 promoter.
- a method of modulating apoptosis and cell- cycle arrest is disclosed, where neoplastic cells are contacted with an agent that modulates expression of SALL4 and/or modulates the expression of Bmi-1.
- such sells are AML cells.
- the modulation reduces expression levels of SALL4 and/or Bmi-1 to induce cell cycle arrest and/or apoptosis.
- such cells can be rescued by restoring Bmi-1 levels to substantially normal.
- apoptosis and cell cycle arrest may be achieved by targeting SALL4 or Bmi-1, or by targeting the combination.
- the induction of apoptosis and/or cell cycle arrest may be accomplished by targeting SALL4 downstream targets.
- a method of modulation of Bmi-1 via SALL4 targeting is disclosed, where such modulation results in apoptosis/cell cycle arrest in cancer stem cells and/or leukemic stem cells, thereby treating cancer in a subject in need thereof.
- SALL4 is an important survival and proliferative factor for NTERA2 cells. Given the observation that SALL4 is also present in other cancer stem cells, SALL4 may be an attractive target for the induction of cancer stem cells to undergo apoptosis.
- SALL4B transgenic mice that exhibit MDS/AML associated with expansion of LSCs are disclosed.
- 5' azacytidine (5AC) or a combination with bortezomib, a proteasome inhibitors is administered to SALL4B transgenic mice and changes are monitored in HSC and HPC subpopulations.
- SALL4B transgenic mice will be treated with a variety of doses. Further, the data will be used to identify an optimal dose that maximizes inhibition of LSC expansion associated with therapeutic responses in SALL4B transgenic mice.
- WHST ⁇ 21413050 1 356077-000029 [0125]
- 5AC is administered alone or a combination with bortezomib to evaluate their effects on the long-term self-renewal ability of LSCs in vitro using serial replating assays.
- the effects of apoptosis on LSCs are also examined by, for example, but not limited to, TUNEL assay and measurement of caspase-3 activity.
- the method determines changes in the expression levels of S ⁇ LL4B; its downstream target, Bmi-1; and its pathways associated with cell growth and/or cell death in HSCs, such as pl6 and pi 9 in transgenic mice, during treatment of 5AC or bortezomib alone or together, by for example, Q-RT-PCR and western blotting.
- Peripheral blood samples may be obtained from SALL4B transgenic mice treated with 5AC or a bortezomib combination with age-matched, untreated control mice. Complete blood cell counts with automated differentials may be determined weekly. The differentials may be confirmed on smears.
- latency of AML transformation may be compared between SALL4B mice treated with 5AC or a combination with bortezomib and untreated SALL4B mice.
- the onset of AML may be monitored by analysis of peripheral blood smears and bone marrow biopsies.
- a method of treating a cancer of stem cell or progenitor cell origin including administrating to a subject in need thereof a composition containing an agent which reduces the expression level of SALL4.
- the agent is an oligonucleotide sequence selected from SEQ ID NO:30, SEQ ID NO:31 ; or SEQ ID NO:32.
- the composition comprises a methylation inhibitor, including but not limited to, 5' azacytidine, 5' aza-2-deoxycytidine, 1-B-D- arabinofuranosyl-5-azacytosine, or dihydroxy-5-azacytidine.
- the composition further comprises a proteasome inhibitor, including but not limited to, MG 132, PSI, lactacystin, epoxomicin, or bortezomib.
- GCTs Germ cell tumors
- WEST ⁇ 21413050.1 356077-000029 Seminoma and embryonal carcinoma are clearly primitive cells with the potential to differentiate into many other cell lines. Immature teratomas and yolk sac tumors are called tissue stem cells because they have a pluripotent potential but can only differentiate further into cells of a specific tissue. The mature teratomas do not express SALL4, which is consistent with the fact that they do not have the ability to differentiate any further.
- SALL4 is strongly expressed in germ cells but not in any other cells of the seminiferous tubules.
- SALL4 is expressed in an undifferentiated embryonal carcinoma cell line, but after induced differentiation, its expression is down-regulated.
- SALL4 is also not expressed in a significant number of cells derived from normal of cancerous epithelial tissues .
- the tissue types represented in a tissue array may contain less than 2% of cells that stain positive for SALL4.
- cells that stain positive for SALL4 in the arrays are indicative of tissue stem cells.
- the staining of the seminiferous tubules with the SALL4 antibody is unique in that only the germ cells of the tubule stained positive for SALL4. Moreover, both germ cells of seminferous tubules and those of various primitive malignant GCTs stain positive for SALL4.
- a method of diagnosing disorders of primordial cell origin in a subject including determining the expression of SALL4 in a tissue sample from the subject.
- the disorder is associated with a germ cell tumor (GCT).
- GCT germ cell tumor
- the GCT includes classic seminoma, spermatocytic seminoma, embryonal carcinoma, yolk sac tumor, or immature teratoma.
- the tissue sample comprises cells of testicular origin, including that substantially all mature testicular cell types present in the sample do not express SALL4. Further, the tissue sample may be obtained from a site which comprises cells that have metastasized from a GCT.
- a method of monitoring engraftment of transplanted stem cells in a subject including determining the level of expression of SALL4 in stems cells prior to transplantation into a subject, grafting the cells into the subject, and determining the level of expression of SALL4 in the grafted stem cells at time intervals post-transplantation, where a decrease in SALL4 expression over the time interval correlates with differentiation of
- an increase in SALL4 expression over the time interval correlates with repression of differentiation, and wherein such repression is indicative of negative engraftment of cells in the subject.
- Such intervals may be from about 1 to 4 hour, about 4 to 12 hours, about 12 to 24 hours, about 24 to 48 hours, about 48 to 72 hours, about 3 to 7 days, about 7 days to 2 weeks, about 2 weeks to 1 month, about 1 to 6 months, and/or about 6 months to a year.
- the cell is transformed by a vector encoding an exogenous or endogenous gene product.
- a method for isolating stem cells from cord blood including obtaining umbilical cord cells (UBC) from a subject, sorting cells that express SALL4 from cells that do not express SALL4, where UBCs expressing SALL4 are indicative of isolated stem cells. Further, the method may include, optionally, selecting by one or more markers, cells from the sorted cells that express SALL4.
- UBC umbilical cord cells
- the one or more markers are selected from the group consisting of SSEA-I, SSEA-2, SSEA-4, TRA-1-60, TRA-I -81, CD34+, CD59+, Thyl/CD90+, CD381o/-, C- kit-/lo, Hn-, SH2, vimentin, periodic acid Schiff activity (PAS), FLKl, BAP, and acid phosphatase.
- a method for detecting the presence or absence of the polynucleotide comprising a nucleic acid sequence encoding SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 in a biological sample including, but not limited to, contacting the biological sample under hybridizing conditions with a probe comprising a fragment of at least 15 consecutive nucleotides of a polynucleotide having a sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5, or a complement of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5, and detecting hybridization between the probe and the sample, where hybridization is indicative of the presence of the polynucleotide.
- WEST ⁇ 21413 05 0.1 3 5 6077-G00029 biological sample including, but not limited to, providing an antibody that binds to the polypeptide, contacting the biological sample with the antibody, and determining the binding between the antibody to the biological sample, where binding is indicative of the presence of the polypeptide.
- a method of treating myelodysplastic syndrome (MDS) in a subject including administering to the subject a polynucleotide having a nucleic acid sequence as set forth in SEQ ID NO: 1, SEQ ID NO; 3, SEQ ID NO: 5, a complement of SEQ ID NO: 1, a complement of SEQ ID NO: 3, a complement of SEQ ID NO: 5, or fragments thereof comprising at least 15 consecutive nucleotides of a polynucleotide encoding the amino acid sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6.
- the method includes administering a polynucleotide as set forth in SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5.
- the MDS is acute myeloid leukemia (AML).
- a method of identifying an agent which modulates the effect of a SALL family member protein on OCT4 expression including co-transfecting a cell with a vector comprising a promoter-reporter construct, wherein the construct comprises an operatively linked OCT4 promoter and a nucleic acid encoding gene expression reporter protein, and a vector comprising a nucleic acid encoding a SALL family member protein, contacting the cell with an agent, and determining the activity of the promoter-reporter construct in the presence and absence of the agent, where determining the activity of the promoter-reporter construct correlates with the effect of the agent on SALL family member protein/OCT4 interaction.
- the promoter region comprises nucleic acid sequence including but not limited to, SEQ ID NO:26, and the expression reporter protein is luciferase.
- a method of treating a neoplastic or proliferative disorder, where cells of a subject exhibit de-regulation of self-renewal including administering to the subject a pharmaceutical composition containing an agent which inhibits the expression of SALL4.
- a method of identifying a substance which binds to a polypeptide including an amino acid sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 comprises contacting the polypeptide with a candidate substance and detecting the binding of the substance to the polypeptide.
- a method of identifying a substance which modulates the function of a polypeptide including an amino acid sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 is disclosed, where the method includes contacting the polypeptide with a candidate substance and determining the activity of the polypeptide, and where a change in the activity in the presence of the candidate substance is indicative of the substance modulating the function of the polypeptide.
- a method of diagnosing myelodysplastic syndrome (MDS) in a subject including, but not limited to, providing a biological sample from the subject, contacting the biological sample with a probe having a fragment of at least 15 consecutive nucleotides of a polynucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, a complement of SEQ ID NO: 1 , a complement of SEQ ID NO: 3, or a complement of SEQ ID NO: 5 under hybridization conditions, and detecting the hybridization between the probe and the biological sample, where detecting of hybridization correlates with MDS.
- the MDS is acute myeloid leukemia (AML).
- a method of diagnosing a myelodysplastic syndrome (MDS) in a subject including, but not limited to, providing a biological sample from the subject, contacting the biological sample with an antibody which binds to a polypeptide comprising an amino acid as set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, and detecting the binding of the antibody to the sample, where detecting binding correlates with MDS.
- the MDS is acute myeloid leukemia (AML).
- a method of diagnosing a neoplastic or proliferative disorder including contacting a cell of a subject with an agent that detects the expression of a SALL family member protein and determining whether a SALL family member protein is expressed in the cell, where determining the expression of the SALL family member protein positively correlates with induction of self-renewal in the cell, whereby such expression is indicative of neoplasia or proliferation.
- the agent is labeled and the determining step includes detection of the agent by exposing the subject to a device which images the location of the agent.
- the images are generated by magnetic resonance, X-rays, or radionuclide emission.
- a method of modulating the cellular expression of a polynucleotide encoding a zinc finger transcriptional factor which is constitutively expressed in primary acute myeloid leukemia cells including introducing a double stranded RNA (dsRNA) which hybridizes to the polynucleotide, or an antisense RNA which hybridizes to the polynucleotide, or a fragment thereof, into a cell.
- dsRNA double stranded RNA
- the modulating is down- regulating.
- antibody directed against human SALL4 is used to characterize subsets of stem cells in hemangiomas, where such antibodies bind to SALL4 expressing cells, which cells are putative pluripotent stem cells.
- SALL4 expressing cells which cells are putative pluripotent stem cells.
- 5 to 10% of the cells comprising hemangiomas bind to such SALL4 directed antibodies.
- diagnosis and monitoring of hemangioma involution can be determined by as decrease in SALL4 binding by such antibodies.
- the monitoring may include, but is not limited to, flow cytometry and/or examination of tissue sections of cells immunohistochemically stained with anti-SALL4.
- non-surgical treatment for infantile hemangiomas where an agent which reduces SALL4 expression is administered to a subject in need thereof in an amount sufficient to cause induction of involution of the hemangiomas in the subject.
- a transgenic animal is disclosed.
- a transgenic animal is produced by the introduction of a foreign gene in a manner that permits the expression of the transgene.
- Methods for producing transgenic animals are generally described by Wagner and Hoppe (U.S. Pat. No. 4,873,191; which is incorporated herein by reference), Brinster et al. (1985); which is incorporated herein by reference in its entirety) and in "Manipulating the Mouse Embryo; A Laboratory Manual" 2nd edition (eds., Hogan, Beddington,
- a gene is transferred by microinjection into a fertilized egg.
- the microinjected eggs are implanted into a host female, and the progeny are screened for the expression of the transgene.
- Transgenic animals may be produced from the fertilized eggs from a number of animals including, but not limited to reptiles, amphibians, birds, mammals, and fish.
- DNA clones for microinjection can be prepared by any means known in the art.
- DNA clones for microinjection can be cleaved with enzymes appropriate for removing the bacterial plasmid sequences, and the DNA fragments electrophoresed on 1% agarose gels in TBE buffer, using standard techniques.
- the DNA bands are visualized by staining with ethidium bromide, and the band containing the expression sequences is excised.
- the excised band is then placed in dialysis bags containing 0.3 M sodium acetate, pH 7.0. DNA is electroeluted into the dialysis bags, extracted with a 1:1 phenol: chloroform solution and precipitated by two volumes of ethanol.
- the DNA is redissolved in 1 ml of low salt buffer (0.2 M NaCl, 20 mM Tris, pH 7.4, and 1 mM EDTA) and purified on an Elutip-DTM column.
- the column is first primed with 3 ml of high salt buffer (1 M NaCl, 20 mM Tris, pH 7.4, and 1 mM EDTA) followed by washing with 5 ml of low salt buffer.
- the DNA solutions are passed through the column three times to bind DNA to the column matrix. After one wash with 3 ml of low salt buffer, the DNA is eluted with 0.4 ml high salt buffer and precipitated by two volumes of ethanol. DNA concentrations are measured by absorption at 260 nm in a UV spectrophotometer.
- the present invention also provides pharmaceutical compositions comprising at least one compound capable of treating a disorder in an amount effective therefore, and a pharmaceutically acceptable vehicle or diluent.
- the compositions of the present invention may contain other therapeutic agents as described, and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques such as those well known in the art of pharmaceutical formulation.
- compositions employed as a component of invention articles of manufacture can be used in the form of a solid, a solution, an emulsion, a dispersion, a micelle, a liposome, and the like, where the resulting composition contains one or more of the compounds
- WEST ⁇ 2141 3 0S0.1 356077-000029 described above as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications.
- Compounds employed for use as a component of invention articles of manufacture may be combined, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use.
- the carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form.
- auxiliary, stabilizing, thickening and coloring agents and perfumes may be used.
- invention pharmaceutical compositions may be administered by any suitable means, for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intracisternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents.
- suitable means for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intracisternal injection or infusion techniques (e.g., as sterile injectable aqueous
- the present compounds may, for example, be administered in a form suitable for immediate release or extended release. Immediate release or extended release may be achieved by the use of suitable pharmaceutical compositions comprising the present compounds, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps.
- the present compounds may also be administered liposomally.
- mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated.
- the method can also be practiced in other species, such as avian species (e.g., chickens).
- the subjects treated in the above methods, in which cells targeted for modulation is desired are mammals, including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species, and preferably a human being, male or female.
- WESTU H 13050 1 356077-000029
- terapéuticaally effective amount means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- administering a should be understood to mean providing a compound of the invention to the individual in need of treatment.
- compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients.
- the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
- the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases.
- compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
- compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
- Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- WbST ⁇ 21413050 1 3 5 6077-000029 excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated to form osmotic therapeutic tablets for control release.
- Formulations for oral use may also be presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules where the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example peanut oil, liquid paraffin, or olive oil.
- Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propyhnethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbito
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- preservatives for example ethyl, or n-propyl, p-hydroxybenzoate
- coloring agents for example ethyl, or n-propyl, p-hydroxybenzoate
- coloring agents for example ethyl, or n-propyl, p-hydroxybenzoate
- flavoring agents for example ethyl, or n-propyl, p-hydroxybenzoate
- sweetening agents such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring
- WEST ⁇ 2141 3 050.1 3 5 6077-000029 agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., sodium EDTA
- suspending agent e.g., sodium EDTA
- preservatives e.g., sodium EDTA, sodium bicarbonate, sodium bicarbonate
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
- This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
- the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- the compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- Such materials are cocoa butter and polyethylene glycols.
- creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention are employed.
- topical application shall include mouthwashes and gargles).
- Nucleic acid according to the present disclosure encoding a polypeptide or peptide able to interfere with SALL4 may be used in methods of gene therapy, for instance in treatment
- Vectors such as viral vectors have been used in the art to introduce nucleic acid into a wide variety of different target cells. Typically the vectors are exposed to the target cells so that transfection can take place in a sufficient proportion of the cells to provide a useful therapeutic or prophylactic effect from the expression of the desired polypeptide.
- the transfected nucleic acid may be permanently incorporated into the genome of each of the targeted tumour cells, providing long lasting effect, or alternatively the treatment may have to be repeated periodically.
- a variety of vectors both viral vectors and plasmid vectors, are known in the art, see U.S. Pat. No. 5,252,479 and WO 93/07282.
- viruses have been used as gene transfer vectors, including papovaviruses, such as SV40, vaccinia virus, herpesviruses, including HSV and EBV, and retroviruses.
- papovaviruses such as SV40
- vaccinia virus such as SV40
- herpesviruses including HSV and EBV
- retroviruses including a virus transfer vectors
- Many gene therapy protocols in the art have used disabled murine retroviruses.
- nucleic acid into cells includes electroporation, calcium phosphate co-precipitation, mechanical techniques such as microinjection, ballistic methods, transfer mediated by liposomes, and direct DNA uptake and receptor-mediated DNA transfer.
- Receptor-mediated gene transfer in which the nucleic acid is linked to a protein ligand via polylysine, with the ligand being specific for a receptor present on the surface of the target cells, is an example of a technique for specifically targeting nucleic acid to particular cells.
- an appropriate dosage level will generally be about 0.01 to 500 mg per kg patient body weight per day which can be administered in single or multiple doses.
- the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably about 0.5 to about 100 mg/kg per day.
- a suitable dosage level may be about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day. Within this range the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg per day.
- compositions are preferably provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0. 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0,
- the compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
- SALL4 isoforms Plasmid construction and DNA sequencing were performed in accordance with standard procedures.
- PCR primers were designed, based on the genomic clone RP5-1112F19 (SEQ ID NO: 25) (GenBank accession no. AL034420).
- SALL4 isoforms were cloned with the use of the Marathon-Ready cDNA library derived from human fetal kidney (BD Biosciences Clontech, Palo Alto, CA), according to the supplier's protocol.
- the amplified PCR products were cloned into a TA Cloning vector (Invitrogen Corp., Carlsbad, CA), and the nucleotide sequences were determined by DNA sequencing.
- the GAL4-SALL4B construct was generated by PCR with the use of a 5' primer and a 3' primer with a restriction enzyme site, BamHI, at each end:
- 5' primer 5'-TTATCAGGATCCTGGTCGAGGCGCAAGCAGGCGAAACCC-S' (SEQ ID NO: 7);
- the GAL4-SALL4B construct was expected to encode 93 amino acids of minimal GAL4 DNA-binding domain and the full length of SALL4B, except for the first amino acid, methionine.
- RT-PCR Reverse transcription-PCR was used to evaluate mRNA expression patterns of SALL4 in adult tissues.
- PCR amplification was performed in a 50- ⁇ l reaction volume containing 5 ⁇ l of cDNA, 10 mM Tris HCl (pH 8.3), 50 mM KCl, 2 mM MgCl 2 , 0.2 mM dNTPs, and 1.25 U of Taq DNA polymerase (PerkinElmer Life Sciences, Boston, MA).
- Amplification of glyceraldehyde phosphate dehydrogenase (GAPDH) mRNA was used to control for template concentration loading.
- the primer pairs selected specifically for SALL4 isoforms were the following:
- SALL4A primers sense primer: 5'-ATTGGCACCGGCAGTTACCACC (SEQ ID NO: 9); antisense primer: 5'-AGTACTCGTGGGCATATTGTC-S' (SEQ ID NO: 10)) and
- SALL4B primers (sense primer: 5'-ATGTCGAGGCGCAAGCAGGCGAAAC-S' (SEQ ID NO: 11); antisense primer: 5'-TTAGCTGACCGCAATCTTGTTTTCT-S' (SEQ ID NO: 12)).
- PCR products were electrophoretically separated on 1% agarose gel. DNA sequencing was also used to confirm amplification products.
- the peptide MSRRKQ AKPQHIN (SEQ ID NO: 13) of human SALL4 was chosen for its potential antigenicity (amino acids 1-13) and used to prepare an antipeptide antibody. This region is also identical to that of mouse SALL4 so that the generated antibody could be expected to cross-react with mouse SALL4.
- S ALL4 antipeptide antibody was produced in rabbits in collaboration with Lampire Biological Laboratories Inc. (Pipersville, PA).
- SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
- RNA assay was used (Applied Biosystems, Foster City, CA) in these studies.
- Total RNA from purified CD34+ HSCs/HPCs from normal bone marrow and peripheral blood, 15 AML samples, and three leukemia cell lines was isolated with the RNeasy Mini Kit and digested with DNase I (Qiagen).
- RNA (1 ⁇ g) was reverse-transcribed in 20 ⁇ L with the use of Superscript II reverse transcriptase and a poly(dT)12-18 primer (Invitrogen). After the addition of 80 ⁇ L of water and mixing, 5- ⁇ L aliquots were used for each TaqMan reaction.
- TaqMan primers and probes were designed with the use of Primer Express software version 1.5 (Applied Biosystems).
- Real-time PCR for SALL4 and GAPDH was performed with the TaqMan PCR core reagent kit (Applied Biosystems) and an ABI Prism 7700 Sequence Detection System (PE Applied Biosystems).
- the PCR reaction mixture contained 3.5 mM MgCl 2 ; 0.2 mM each of deoxyadenosine triphosphate (dATP), deoxycytidine triphosphate (dCTP), and deoxyguanosine triphosphate (dGTP); 0.4 mM deoxyuridine triphosphate (dUTP); 0.5 ⁇ M forward primer; 0.5 ⁇ M reverse primer; 0.1 ⁇ M TaqMan probe; 0.25 U uracil DNA glycosylase; and 0.625 U AmpliTaq Gold polymerase in 1 x TaqMan PCR buffer.
- cDNA (5 ⁇ L) was added to the PCR mix, and the final volume of the PCR reaction was 25 ⁇ L. All samples were run in duplicate. GAPDH was used as an endogenous control. Thermal cycler conditions were 50°C for 2 min,
- GAPDH forward primer (5'-GAAGGTGAAGGTCGGAGTC-S' (SEQ ID NO: 14)) and reverse primer: (5'-GAAGATGGTGATGGGATTTC-S' (SEQ ID NO: 15)), TaqMan probe: (5'-CAAGCTTCCCGTTCTCAGCC-S' (SEQ ID NO: 16)), and SALL4 forward primer: (5'- CCTCCTAATGAGAGTATCTGGGTGAT-3' (SEQ ID NO: 17)) and reverse primer: (5'- TTAAAAC ATACAGCGCATGATTGG-S' (SEQ ID NO: 18)).
- Tissue arrays that included triplicate tumor cores from leukemia specimens were sectioned (5 ⁇ m thick).
- a manual tissue arrayer (Beecher Instruments, Silver Spring, MD) was used to construct the tissue arrays.
- Immunohistochemical staining was performed according to standard techniques. Briefly, formalin-fixed, paraffin-embedded, 4- ⁇ m-thick tissue sections were deparafinized and hydrated. Heat-induced epitopes were retrieved with a Tris buffer (pH 9.9; Dako Corp., Carpinteria, CA) and a rapid microwave histoprocessor. After incubation at 100°C for 10 min, slides were washed in running tap water for 5 min and then with phosphate buffered saline (PBS; pH 7.2) for 5 min. Tissue sections were then incubated with anit-SALL4 antibody (1 :200) for 5 h in a humidified chamber at room temperature. After three washes with PBS, tissue sections were incubated with antimouse immunoglobulin G and peroxidase for 30 min at room temperature.
- Tris buffer pH 9.9; Dako Corp., Carpinteria, CA
- PBS phosphate buffered saline
- Neoplastic cells were considered to be positive for SALL4 when they showed definitive nuclear staining.
- SALL4B cDNA corresponding to the entire coding region, was subcloned into a pCEP4 vector (IntroGene; now Crucell, Leiden, The Netherlands) to create the CMV/SALL4B construct for the transgenic experiments. Subsequent digestion with Sail, which does not cut within the SALL4B cDNA, released a linear fragment containing only the CMV promoter, the SALL4 cDNA coding region, the SV40 intron, and polyadenylation signal without additional vector sequences.
- pCEP4 vector IntroGene; now Crucell, Leiden, The Netherlands
- Transgenic mice were generated via pronuclear injection performed in the transgenic mouse facility at Yale University. Identification of SALL4B founder mice and transmission of the transgene was determined by PCR analyses.
- the PCR primers used for the genotyping span the junction of the 5' SALL4B cDNA to the CMV promoter (sense primer: 5'-CAGAGATGC TGAAGAACTCCGCAC-3' (SEQ ID NO: 19); antisense primer: 5'- AGCAGAGCTCGTTTAGTGAACCG-3' (SEQ ID NO: 20)).
- HEK-293 ATCC: CRL- 112678 cells were cultured in Dulbecco modified Eagle medium (DMEM) supplemented with 10% heat-inactivated FBS (fetal bovine serum) and penicillin/streptomycin (P/S).
- DMEM Dulbecco modified Eagle medium
- FBS fetal bovine serum
- P/S penicillin/streptomycin
- the HL60 cell line was cultured in RPMI 1640 medium supplemented with 10% FBS and P/S.
- a murine hemopoietic multipotential cell line, 32D was maintained in RPMI 1640 supplemented with 10% FBS, P/S, and mouse leukemia inhibitory factor (mLIF; 1 x 103 U/ml, Chemicon, Pittsburgh, PA).
- Plasmid DNA for transient transfection was prepared with the Qiagen Plasmid Midi Kit (Valencia, CA).
- the cells were extracted with 100 ⁇ l of luciferase cell culture lysis reagent (Promega Corp., Madison Wi) 24 h after transfection.
- the ⁇ -galactosidase assay performed with 10 ⁇ l of cell extract, used the ⁇ -Galactosidase Enzyme Assay System (Promega) and the standard assay protocol provided by the manufacturer (except that 1 M Tris base was used as stopping buffer, instead of sodium carbonate).
- luciferase assay Promega
- 5 ⁇ l of extract were used in
- an OCT4-Luc construct comprising an OCT4 promoter (SEQ ID NO:26) or SALL-Luc construct containing a SALL family protein (i.e., SALLl, SALL3, SALL4A, or SALL4B) promoter (i.e., SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29, respectively, where SALL4A and SALL4B share the same promoter) was cotransfected with between 0.1 ⁇ g and 0.12 ⁇ g of renilla plasmid and/or various amounts (0-1.0 ⁇ g) of plasmid expressing SALL family proteins or OCT4 protein in HEK-293 or COS-7 cells.
- pcDNA3 vector was used as the control. Transfected cells were then monitored for luciferase activity 24 hour s post-transfection.
- Human EC cell line NTERA2.cl.Dl (ATCC#CRL-1973) was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS (fetal bovine serum). Cells were induced to differentiate by treatment with different amounts of retinoic acid (Sigma). Phoenix packaging cells (ATCC: #SD-3443) are cultured by means well known in the art.
- DMEM Dulbecco's modified Eagle's medium
- FBS fetal bovine serum
- Phoenix packaging cells (ATCC: #SD-3443) are cultured by means well known in the art.
- siRNA oligonucleotides (#7410, #7412; Origen, Rockville, MD) that targeted different regions of the SALL4 gene were transfected into Phoenix packaging cells using Lipofectamin 2000. Shed virus was harvested. NTERA2 cells were infected with the virus collected 48 hours post-transfection. Stable SALL4 knockdown NTERA2 clones were obtained
- the 5'-flanking region of Bmi-1 was amplified with primers (5 1 primer: 5'-CAT CCT CGA GGG CTG TTG ACA TCT GCA GAG ACT G -3'; 3' primer: TCG TAG ATC TCA TTT CTG CTT GAT AAA AGA TCC TGG -3') to generate a fragment from nucleotide (Nt) -1 to Nt- 2102 upstream of the starting codon ATG with Xhol and BgIII sites at each end respectively.
- Mouse genomic DNA isolated from ESCs was used as a template.
- the amplified PCR (polymerase chain reaction) fragment was cloned into the promoterless pGL3 -basic luciferase reporter plasmid (Promega, Madison, WI) to generate plasmid Bmi-1 (P2102) (i.e. Nt-I to -2102, see Fig. l).
- Bmi-1 plasmid Bmi-1
- Promoter fusion reporter fragments from Nt-I to -1254, -683, -270 and -168 were created in the same manner as Bmi-1.
- SEQ ID NO:30 (5'-gatcccccaacatcccttctgccaccttcaagagaggtggcagaagggatgttgtttttc-3')
- SEQ ID NO:31 (5'-gatcccccaccactgatcccaacgaattcaagagattcgttgggatcagtggtgttttttc-3')
- SEQ ID NO:32 (5'-gatcccctcatttgccaccgagtcttttcaagagaaagactcggtggcaaatgattttttc-3').
- the Phoenix packaging cells (ATCC: SD-3443) were grown in DMEM with 10% FBS in 5% CO 2 at 37°C. Recombinant retroviruses were produced using the Phoenix packaging cell line that was transfected with the pSuper construct containing the control RNAi sequence or sequence directed against SALL4. The viral supernatant was collected 48 hours after transfection and filtered through a 0.45- ⁇ m filter.
- Bmi-1 promoter luciferase assays were performed with the Dual-Lucif erase Reporter Assay System (Promega, Madison WI). Twenty-four hours after transfection, HEK-293 cells were extracted with the use of a passive lysis buffer; a 20- ⁇ l aliquot was used for luminescence measurements with a luminometer. The data are represented as the ratio of firefly to Renilla luciferase activity (Fluc/Rluc). These experiments were performed in duplicate.
- HEK-293 32D cells (1 x 10 6 cells/well in 6-well plates), with or without transient transfection, were processed using a ChIP Assay Kit (Upstate, Charlottesville, VA) following the manufacture's protocol. Briefly, cells were cross-linked by adding formaldehyde (27 ⁇ l of 37% formaldehyde/ml) and incubated for 10 min. Then, chromatin was sonicated to an average size of approximately 500 bp and immunoprecipitated with SALL4 antibodies, preimmune serum, or anti-HA (hemagglutination) antibody.
- SALL4 antibodies preimmune serum
- anti-HA hemagglutination
- DMSO Dimethylsulfoxide
- W4 mouse ESCs (kindly provided by the Gene Targeting Core Facility, University of Iowa) either on feeders or in feeder-free conditions were cultured as described previously.
- G418 was added in the media at a concentration of 125ug/ml.
- a complete protocol was provided by NimbleGen Systems Inc (Madison, WI). In brief, cells were grown, cross-linked with formaldehyde and sheared by sonication. The anti- SALL4 antibody and rabbit serum (ref.) were used for chromatin immunoprecipitation (CHIP). CHIP -purified DNA was blunt-ended, ligated to linkers and subjected to low-cycle PCR amplification.
- Promoter tiling arrays (RefSeq array) were produced by NimbleGen.
- the RefSeq mouse promoter array design is a single array containing 2.7kb of each promoter region (from build MM5). The promoter region is covered by 50-75 mer probes at roughly lOObp spacing dependent on the sequence composition of the region. The arrays were hybridized, and the data were extracted according to NimbleGen standard procedures.
- a custom mieroarray was manufactured by NimbleGgen (Madison, WI) using maskless array synthesis.
- Ten probe pairs for each target were selected from the 3' 1 kb of each target. Probes were spaced evenly over the length of the target region (Sl kb), so that the exact spacing depended on the length of the target sequence. Each probe was 24 nucleotides in length. For each perfect match probe there was also a mismatch probe, which differed by a single nucleotide.
- WESTV21413QS0 1 3 5 6077-00CI029 differed from the mean for the set by more than 3 SD were removed from the set and the mean recalculated. Average differences (recalculated mean) were used for subsequent analysis. Data analysis was performed using PANTHER and Ingenuity Pathway Analysis.
- plasmid pcDNA3/S ALL4-H ⁇ was transfected into W4 ES cells to express SALL4-HA fusion protein.
- Lipofectamine 2000 reagent (Invitrogen) was used based on provided instructions. After 36 hours, cells were collected and treated with CelLytic M Cell Lysis Reagent (Sigma). The immunocoprecipitation were performed following the Catch and Release v2.0 Kit (Upstate) recommendations.
- W4 lysates were incubated with the anti-HA antibody (Bethyl Laboratories Inc.) or IgG at 25°C for 40 minutes, protein bound to the beads was then washed and eluted with denaturing elution buffer containing 0.5% ⁇ -mercaptoethanol.
- Western blot was performed as described (ref.). The membrane was incubated with Oct-3/4 (H- 134), Nanog (M- 149) (both from Santa Cruz) or SALL4 antibodies at a 1 :300 dilution at 4 0 C overnight. Detection was done by using the SuperSignal West Pico solutions (Pierce).
- the SALL4-flox vector was constructed by incorporating the 5' Notl-Sall 2 kb fragment, the T Bamlfl ⁇ oxp-Pacl-Kpnl 3.2 kb fragment and the PacVKpr ⁇ . 3.4 kb fragment into a vector that contained pGK-Neo flanked by FRT and loxP sequences. LoxP sequences were placed so that exon 2 was excised upon Cre treatment, resulting in disruption of 6 zinc-finger motifs. These ES cells were infected with Ad-CMV-Cre or Ad-CMV-GFP (#1045 and #1060 Vector BioLabs) following the manufacturer's procedures. Conventional SALL4 deficient ES cells were established by methods known in the art.
- SALL4A Single, large open reading frame
- SALL4B The other splicing variant of SALL4, designated SALL4B, lacked the region corresponding to amino acids 385—820 of the full-length SALL4A (Fig. Ia).
- the putative protein encoded by SALL4B cDNA was expected to consist of 617 amino acids.
- SALL4A contained all exons (1—4) (Fig. Ia), whereas SALL4B lacked the 3' large portion of exon 2. Both exon-intron splice sites satisfied the G-T-A-G rule. Both splicing variants had the same translational reading frame, but SALL4B mRNA encoded a protein with internal deletions. SALL4A contained eight zinc finger domains, while SALL4B had three zinc finger domains.
- SALL4 The alternative splicing patterns of SALL4 were delineated by reverse transcription (RT)-PCR in a variety of human tissues.
- a fragment of the ubiquitous GAPDH gene cDNA was amplified as a control (Fig. Ib).
- a 315-bp fragment representing the longer splice variant, SALL4A was amplified in some tissues, achieving various expression levels.
- the SALL4B variant was present in every tissue at varying levels of expression. Detailed studies on S ALL4 expression in hematopoietic tissues are described in the following results.
- SALL4 gene products and confirm the presence of SALL4 variants.
- a polyclonal antibody against a synthetic peptide (amino acids 1-13) of SALL4 was developed. This region was chosen because it is common to both SALL4 variants.
- the affinity-purified SALL4 peptide antibody recognized specifically two endogenous proteins in a human kidney total lysate. The two proteins were approximately 165 kDa and 95 kDa, which were identical to the molecular weights of overexpressed S ALL4A and SALL4B in Cos-7 cells, respectively (Fig. Ic). Western blotting with this antibody confirmed that the SALL4 isoforms had different tissue distributions that were similar to those observed at the mRNA level (Fig. Ib-B).
- SALL4 mRNA expression in AML was examined.
- HSCs/HPCs purchased from Cambrex
- SALL4B and/or SALL4A failed to be turned off (S ALL4B) or down-regulated (S ALL4 A) in all AML samples and myeloid leukemia cell lines.
- the data were normalized to the endogenous expression of GAPDH and calibrated against the level of S ALL4A or S ALL4B expression in purified CD34+ cells.
- SALL4B failed to be turned off in 13 of 15 AML samples and in all three myeloid leukemia cell lines.
- the median normalized level of SALL4A in primary AML samples was 40-fold higher than that in normal bone marrow.
- SALL4A expression levels in the myeloid leukemia cell lines KG.l, Kasumi-1, and THP-I were, respectively, 8-, 25-, and 240-fold higher than those in normal bone marrow.
- both SALL4A and SALL4B expression levels were increased in 60% of AML samples and in all three cell lines, compared with those in normal bone marrow. In the remaining 40% of AML samples, either SALL4A or SALL4B failed to be down-regulated.
- S ALL4 transgenic mouse model was generated.
- the CMV promoter was fused to cDNA that encoded the 617 amino acids of human SALL4B (Fig. 3 a- A), which was chosen because it was expressed in every tissue previously examined (Fig. Ib-B).
- the CMV promoter was previously used to ectopically express human genes in most murine organs.
- RT-PCR amplification was performed to examine the overexpression of wildtype (WT), full-length SALL4B in the transgenic mice.
- a SALL4B transcript was detected in a variety of tissues from the transgenic mice, including brain, kidney, liver, spleen, peripheral blood, lymph nodes, and bone marrow (Fig. 3 a- B). Abnormal gaits and associated hydrocephalus 3 weeks after birth were observed in 20% of the transgenic mice from multiple lines; 60% had polycystic kidneys.
- 507 F 507 24 AML Died, AML in BM, PB, Liver, Spleen, LNs
- Leukemia blast cells were considered to be myeloid in origin because they were positive for CD34, c-kit, Gr-I, Mac-1, MPO, and nonspecific esterase; they were negative for B-cell (B220 and CD 19), T-cell (CD4, CD8, CD3, and CD5), megakaryocyte (CD41), and erythroid (Terl 19) markers (Fig. 3d).
- a luciferase reporter (TOPflash; Upstate USA) containing multiple copies of Wnt- responsive elements to determine the potential of SALL4A and SALL4B to activate the canonical Wnt signaling pathway was used.
- This reporter construct has been shown to be efficiently stimulated by Wntl in a variety of cell lines.
- TOPflash reporter plasmid was transiently transfected in the HEK-293 cell line, in which both Wnt and its Wnt/ ⁇ -catenin signal pathways were present.
- TOPflash reporter plasmid was also cotransfected with SALL4A or SALL4B. Significant activation of the Wnt/ ⁇ -catenin signaling pathway by both SALL4A and SALL4B was indicated by increased luciferase activity (Fig. 4b).
- Dysregulated Wnt/ ⁇ -catenin signaling is known to be involved in the development of LSCs.
- the best evidence for ⁇ -catenin's involvement in LSC self-renewal comes from the study of CML blast transformation. It has been demonstrated that Wnt signaling was activated in the blast phase of CML but not the chronic phase, where it was concluded that dysregulated Wnt signaling, such as activation of ⁇ -catenin, could confer the property of self-renewal on the GMPs of CML and lead to their blastic transformation.
- OCT4-Luc constructs were co- transfected with renilla plasmids and increasing concentrations of SALL4B (FIG. 5). As the figure shows increasing SALL4B increased OCT4 promoter activity by more than 8 fold.
- promoter constructs (pSALLl, pSALL3, and pSALL4) were co-transfected with OCT4 in HEK- 293 cells.
- FIG. 6 shows that after 24 hr post-transfection, the overexpression of OCT4 strikingly stimulated the promoter activities of SALL gene members SALLl, SALL3, and SALL4 when compared with that of the pcDNA3 vector control. Also, this activation was totally blocked by the presence of a small amount of excess SALL4 (FIG. 10).
- SALL4-Luc was co-transfected with renilla reporter and either SALL4A or SALL4B expression plasmids is HEK-293 and COS-7 cells (FIG. 7).
- SALL4 both A and B isoforms
- SALL4 suppresses its own promoter activity in different cell lines.
- this self-suppression is dose dependent (see, FIG. 8).
- the ratio of SALL4A with SALL4 promoter reached 6:1, the promoter activity dropped approximately 3.5 fold compared with the basal level. This data indicates that SALL4 bears a self-suppression function. This is not true for all SALL members, for example, SALLl fails to demonstrate self- suppression of its promoter (FIG. 12).
- SALL4 Since the stimulation of OCT4 on SALL4 promoter can be totally blocked by SALL4 (FIG. 10), SALL4 was examined to determine if it represses the activation of OCT4 on other SALL member promoters. As can be seen in FIG. 11, SALL4 also blocked OCT4 activation of other SALL member promoters.
- SALL4 is a key regulator of embryonic stem cells in pluripotency and self-renewal.
- embryonic carcinomas display the phenotype of early embryonic stem cells and possess pluripotent potential. Therefore, the expression of SALL4 protein in this type of tumors by immunohistochemistry was examined. Immunohistochemical data conclusively indicated that all tumor cells of embryonic carcinomas showed a nuclear staining, whereas all non-tumor cells were negative.
- SALL4 was expressed in very early embryonic stem cells, and embryonic carcinoma is reported to arise from transformation of these cells
- immunohistochemistry also shows that a) SALL4 positive cells in normal breast lobules, accounted for less than 2% of the epithelium and b) in breast carcinoma samples, S ALL4 protein expression in clusters of cells or scattered cells was observed. Further, SALL4 protein was expressed in the nucleus of normal breast epithelial cells and breast carcinoma cells. Moreover, this pluripotent gene expression was observed in other normal adult tissues such as prostate and lung, and carcinoma arising from these tissues with S ALL4 antibody.
- SALL4 plays a vital role in governing ES cell fate decisions. SALL4 is expressed early in embryonic development and exhibits a similar expression pattern to that of Oct4. SALL4 -null ES cells exhibited significantly reduced proliferation and microinjection of SALL4 small interfering RNA into mouse zygotes resulted in reduction of S ALL4 and Oct4 mRNAs prior to implantation. These findings prompt the investigation into global downstream targets of SALL4 in embryonic cells. Using a ChIP-chip assay, a genome scale mapping of SALL4 binding genes was carried out in the murine embryonic stem cell line W4.
- both SALL4 and Oct4 are expressed in the very early stage of the embryonic development. SALL4 expression is already seen in the 2-cell stage with Oct4, while Nanog is expressed once development reaches the blastocyst stage. The earlier expression and extensive gene binding may suggest that SALL4 exert an even larger and more massive role in regulating ES cell features.
- SALL4 represses genes leading to differentiation and activates genes that are necessary for pluripotency.
- 217 of the SALL4 bound genes identified as necessary for cell differentiation were analyzed, some of which are specifically expressed in different developmental lineages.
- SALL4 binds with multiple markers from all of the lineages including ectoderm, endoderm, mesoderm and trophectoderm, suggesting a direct involvement in regulating cell differentiation and pluripotency.
- Using our conditional Sall4 knockout ES cell lines we were able to verify changes of these marker expression levels after endogenous SALL4 knockdown.
- WEST ⁇ 214130S0.1 3 5 6077-000029 expression was evaluated by qPCR.
- For differentiation analysis we chose 4 candidate markers for each cell lineage.
- Sall4 binds to tarfiet genes of PRCl and PRC2
- PRCs Polycomb-Repressive Complexes
- PRCl consists of >10 subunits including Bmil, Rnf2, Phcl and the HPC proteins while the PRC2 contains Ezh2, Eed, Suzl2 and RbAp48.
- PRCs maintain ES cell pluripotency through epigenic events such as methylation of lysine 27 on histone 3 (H3K27), thus suppressing differentiation related activators.
- H3K27 histone 3
- Table 4 Key developmental genes bound by Sall4 Hox Genes homeo box A1 Hoxal homeo box A11 Hoxal 1 homeo box A3 Hoxa3 homeo box A4 Hoxa4 homeo box A5 Hoxa ⁇ homeo box A7 Hoxa7 homeo box A9 Hoxa9 homeo box B2 Hoxb2 homeo box B5 Hoxb ⁇ homeo box B6 Hoxb6 homeo box B7 Hoxb7 homeo box B8 Hoxb ⁇ homeo box C10 HoxdO homeo box C11 Hoxd 1 homeo box C4 Hoxc4 homeo box C6 Hoxc ⁇ homeo box C9 Hoxc9 homeo box D10 HoxdiO homeo box D12 Hoxd 12 homeo box D3 Hoxd3 homeo box D4 Hoxd4
- Oocyte Homeobox Family oocyte specific homeobox 1
- Oboxi oocyte specific homeobox 3
- Obox3 oocyte specific homeobox 6
- Other homeobox genes homeo box, msh-like 2 Msx2 even skipped homeotic gene 2 homolog Evx2 aristaless related homeobox gene (Drosophila)
- Cdx4 developing brain homeobox 1 Dbx1 diencephalon/mesencephalon homeobox 1 Dmbxi extraembryonic, spermatogenesis, homeobox 1 Esx1 genomic screened homeo box 2
- Gsh2 homeobox, msh-like 2 Msx2 even skipped homeotic gene 2 homolog Evx2 aristaless related homeobox gene (Drosophila)
- Cdx4 developing brain homeobox 1
- H2.0-like homeo box 1 (Drosophila) HIxI homeobox containing 1 Hmboxi
- Iroquois related homeobox 6 (Drosophila) Irx6 ladybird homeobox homolog 2 (Drosophila) Lbx2 mesenchyme homeobox 2 Meox2
- Unc4.1 homeobox (C. elegans) Uncx4.1 ventral anterior homeobox containing gene 2 Vax2 zinc finger homeobox 1 b Zfhxi b reproductive homeobox 4B Rhox4b reproductive homeobox 7 Rhox7
- genes When genes are associated with bivalent domains, they have been shown to have low expression levels due to the methylation at K27 having a more pronounced effect on expression than the activating K4 methylation. Thus, we would expect the 54 genes identified in this study to have low expression levels in SALL4 expressing cells, but cannot predict the effects of SALL4 shutdown.
- the Nodal pathway belongs to the TGF- ⁇ superfamily, is largely restricted to stem cells and sustains pluripotent cells in the mouse epiblast before axial pattering. Notch signaling pathway affects a diverse range of development processes controlling cell differentiation, proliferation, morphogenesis and organ formation. Since more than 85 SALL4 binding genes are involved in Wnt pathway or as downstream targets, we will use this pathway as an example for further analysis (see below).
- Sall4 knockdown cells spontaneously differentiate. Previous studies have stated that this differentiation is into trophectoderm lineages. Here, it appears as though knockdown results in differentiation into endoderm, ectoderm, and trophectoderm lineages based on real-time PCR. These findings may differ due to different methods of transfection. In our experiment expression levels were measured right after endogenous SALL4 shutdown. This is in contrast to previously published data that use stable transfection and allow other genes to compensate for Sall4 shutdown.
- S ALL4 may be one of few genes that creates a connection between LSCs and the self- renewal properties of normal HSCs and ES cells. Interestingly, SALL4 protein expression is always correlated with the presence of stem and progenitor cell populations in various organ systems including bone marrow.
- Amplification of the SALL4 gene is seen in approximately 75 percent of human AML cases.
- Q-PCR quantitative polymerase chain reaction
- 81 AMI samples ranging from AML subtypes Ml to M5 (FAB classification) were examined. All 81 AML samples have shown aberrant SALL4 expression, which was consistent with the SALL4 mRNA expression levels as demonstrated by real-time polymerase chain reaction (RT- PCR) amplification, hi normal hematopoiesis, SALL4 was present in the CD34 + HSCs/HPCs and down-regulated in mature granulocytes and lymphocytes. As a result, constitutive expression of SALL4 in leukemia may have prevented the leukemic blasts from differentiating and/or gaining self- renewal properties.
- SALL4 protein The expression of the SALL4 protein in human samples containing differing grades of MDS was also examined using immunohistochemistry with an affinity-purified SALL4 antibody. Using a cut-off of >5 percent SALL4 positive cells, all low-grade MDS groups (RA, refractory anemia, and RARS, refractory anemia with ringed sideroblasts) were negative for SALL4. SALL4 positivity — defined as more than 5 percent of immunolabeled cells — was detected in 10 of 11 high-grade MDS groups. The high-grade MDS groups were further contrasted with respect to the percentage of S ALL4 positive cells. RAEB-2 (refractory anemia with excess blasts-2) and AML transformation showed a relatively high percentage (>10 percent). The highest percentage of SALL4 positive cells was seen in AML transformation (>20 percent). This indicates that the high percentage of SALL4-expressing cells correlates with a high-grade morphology in MDS.
- RA refractory anemia
- RARS
- SALL4B transgenic mice are an ideal mouse model for human MDS
- MDS progression is driven by the expansion of a subset of primitive, self-renewing stem cells in our mouse mode
- HSC and HPC sub-populations were analyzed with correlation to disease progression in SALL4B transgenic mice.
- the total number of bone marrow cells was similar among the wild type (WT), pre-leukemic, and leukemic SALL4B transgenic groups.
- the percentages of both HSC and the HPC populations were elevated significantly for pre-leukemic or leukemic stages in SALL4B transgenic mice as compared to the WT control littermates (Fig. 18).
- serial leukemic transplantations were performed using a NOD-SCID.
- the HSC and HPC sub-populations were sorted from primary leukemic SALL4B transgenic donor mice. The sorting was followed with transplantations into NOD-SCID mice. The leukemic phenotype was noticed in the recipients. We observed that the granulocyte/macrophage progenitors (GMP) cells continued to expand in the transplanted leukemia (Fig. 19), becoming the only HPC population after the second transplantation. Similarly, the HSC population was elevated variably in the leukemic donor and its serial recipient mice. Both HSCs and GMP cells can give rise to the leukemic phenotype in the recipients thus indicating that both populations were LSCs. Moreover, BmUl, a gene that plays important roles in self-renewal of LSCs, has been associated with &4ZL4.B-induced LSCs.
- Bmi-1 is the most studied gene in regulating LSC self-renewal properties. Knockout of Bmi-1 in mice results in a progressive loss of all hematopoietic lineages. This loss results from the inability of the Bmi-1 " stem cells to self renew. Bmi-1 " cells display altered expression of the cell-cycle inhibitor genes pi 6 0 ⁇ 43 and pi 9 ARF resulting in the promotion of cell-cycle arrest and apoptosis mainly through the activation of the pRb and p53 pathways. Introducing genes known to produce AML into Brni-1 "7" HSCs induces AML with normal kinetics.
- the Bmi- 1 " " LSCs from primary recipients are unable to produce AML in secondary recipients due to exhaustion of the Bmi-1 " " LSCs.
- SALL4B is highly expressed in HSCs and is down- regulated as differentiation proceeds. The expansion of stem compartments is accompanied with MDS and progression of MDS to AML associated with up-regulated expression of Bmi-1 in the SALL4B mouse model. In addition, our data have shown that the SALL4B gene is able to transactivate Bmi-1.
- siRNA retroviral constructs that target different regions of the SALL4 mRNA were made, and their ability to reduce SALL4 mRNA in NB4 cells was confirmed by Q- RT-PCR.
- down-regulation of SALL4 also significantly reduced Bmi-1 levels. As shown in Fig.
- caspase-3 is one of the key protein markers for the apoptosis pathway. Similar results were observed in other cancer cell lines, such as an embryonic carcinoma (EC) cell line and a chronic myeloid Leukemic cell line, KBM5 (data not shown). In addition, the S ALL4-induced caspase-3 activity was restored to a near normal level by overexpression of Bmi-1 (Fig. 20C).
- mice containing the conditional SALL4 allele(s) (floxed) were generated through homologous recombination.
- LSCs are quite different from leukemic blast cells, and LSCs are not effectively killed by standard chemotherapy drugs. Consequently, even for patients who attain a remission, the LSCs generally are not destroyed and are considered to be responsible for subsequent relapses with the disease.
- SALL4 is an ESC gene and over expression of this gene in mice transforms HSCs/HPCs into LSCs associated with up-regulation of Bmi-1. Reduction of SALL4 triggers massive apoptosis and cell-cycle arrest in AML cells associated with reduction in Bmi-1. These phenomenal responses can be rescued by restoring Bmi-1 to a relatively normal level (see above).
- SALL4 flox/flox and SALL4 flox ⁇ mice are crossed to poly I:C (interferon) -inducible MxlCre mice.
- the MxlCre mouse has been shown to induce high levels of Cre recombinase in almost all cell types in the marrow, including stem cells or very early progenitor cells.
- the Cre recombinase transgene is under the control of the interferon-regulated promoter in such a manner that induction of Cre expression — achieved by injecting poly I:C — causes an excision of a critical exon from the target gene.
- Bone marrow cells from 5-FU (fluorouracil) -treated SALL4 flox/flox /Cre and SALL4 flox/+ /Cre mice will be retro virally transduced with the Hoxa9-Meisl fusion gene and transplanted into a lethally irradiated recipient to generate the AML mouse model. Since LSCs in AML are similar to LSCs in MDS progression with increased leukemic blasts and because there is no mouse model available for MDS progression, we will focus on an AML mouse model.
- AML is demonstrated by a peripheral blood smear, and AML-bearing mice will be injected intraperitoneally with the interferon inducer polyinosinic-polycytidylic (pIpC) to excise the SALL4 gene.
- the deletion of S ALL4 will be monitored to slow the leukemia progression and change the phenotype or clinical presentation.
- Leukemic blasts will be counted by a peripheral blood smear. The lower leukemic blast number in the peripheral blood or bone marrow could
- WESTV21413050.1 3 5 6Q77-000029 indicate an exhaustion of SALL4 " " or SALL4 "/+ LSCs.
- FACS will be used to analyze leukemic blasts. The main reason for analyzing both SALL4 " “ and SALL4 " + LSCs, is because we anticipate a dose- response effect with SALL4 deletion on LSCs.
- transplantation assays are performed. The AML cells derived from the bone marrow of SALL4 7" or SALL4 "/+ mice will be transplanted into synergistic mice. Recipient mice will then be monitored over time for the development of AML.
- AML cells from SALL4 7" or SALL4 "/+ mice will be analyzed for apoptosis and cell-cycle progression. Furthermore, the survival and growth characteristics of AML cells from SALL4 "7” or SALL4 "/+ will be monitored through long-term in vitro cultures.
- Lentiviruses that express Bmi-1 are prepared. Retroviral supernatants will be used to transduce SALL4 "A and SALL4 "/+ AML HSCs/HPCs cells sorted from AML SALL4 7" or SALL4 "/+ mouse marrows. GFP + (green fluorescent protein) and GFP " cells will be FACS-purified. Bmi-1 expression will be assessed by RT-PCR assay. GFP + and GFP " cells of SALL4 '7" AML HSCs/HPCs will be assayed for bone marrow transplantation and colony formation as previously described. If increased Bmi-1 restores the serf renewal ability of SALL4 "7" AML HSCs/HPCs, then the GFP + cells will be transplantable and demonstrate increased replating in long-term culture.
- an RCAS virus that facilitates delivery of siRNA into LSCs that express TVA is used.
- Mice are created that express the receptor for the subgroup A avian leukosis virus (ATV), specifically for HSCs and HPCs in SALL4B mice. This will be achieved by placing the gene which encodes this virus receptor (TVA) under the control of a promoter, scl, that is active only in HSCs and HPCs.
- TVA avian leukosis virus
- SALL4B mice will be crossed to scl-TVA mice to generate SALL4B/scl-TVA mice.
- HSCs and HPCs of SALL4B/scl-TVA mice will express this receptor and be susceptible to infection by ATV, while other tissues cannot be infected because they lack the TVA receptor.
- LSCs of SALL4/scl MDS mice will express the ATV receptor since LSCs are transformed from HSCs and HPCs.
- TVA-based retroviral vectors have been successfully used in the development of cancer models with mice.
- WESTV21413050 1 356077-000029 [0297] MDS progression will be characterized after intravenous and intra-marrow injection of variable titers of RCANBP viruses carrying the SALL4 siRNA sequence (which silences the expression of SALL4).
- Oligonucleotides sequences will be inserted into the RCANBP(A)Hl vector, and the viruses will be produced in DF-I cells.
- a vector containing a scrambled siRNA sequence will be used as a negative control.
- the virus will be tested to reduce SALL4 expression in leukemic cell lines. The extent of the reduction will be assessed at the RNA level using Q-PCR and at the protein level by western analysis. The effect on cell death will be determined by cell count. The efficacy and duration of SALL4 reduction will be determined, as well as the extent of induced cell death, following delivery into blood and marrow of SALL4/ scl-TVA MDS mice.
- mice When SALL4B/scl-TVA mice progress to AML or in early disease, as demonstrated by a peripheral blood smear, RCANBP Hl viruses carrying SALL4 siRNA will be administrated to mice to suppress SALL4 expression.
- the latency, penetrance, immunophenotype, and transformation of AML will be compared between three groups of mice: (a) SALL4B/scl-TVA mice with a control retrovirus, (b) SALL4B/scl-TVA mice with RCANBP Hl viruses carrying SALL4 siRNA, and (c) scl-TVA normal mice.
- the reduction of SALL4 as related to its functions in LSC vs. normal HSCs/HPCs through apoptosis, cell-cycle progression, long-term culture and bone marrow repopulation assays will be compared.
- WESTO 1413050 1 356077-000029 (AML).
- Affymetrix microarray hybridization using Ul 33 chips
- Bmi-1 was identified as one of genes whose expression was significantly increased.
- SALL4 binding region (-270 to -168) then was deleted from the 0 to -1254 and 0 to -683 promoter fragments and two new Bmi-1 promoter constructs created.
- the luciferase activity of the resulting constructs (P 1254 and P683) was compared with activity in the WT promoter constructs with or without co-transfection of SALL4A or SALL4B in HEK-293 cells.
- the myeloid stem cell line 32D expresses Bmi-1 but has very low levels of endogenous SALL4. Binding of SALL4 proteins to the Bmi-1 promoter in 32D cells was analyzed using ChiP assays. 32D cells were transfected with SALL4A and SALL4B cDNA constructs tagged with haemagluttin (HA). Chromatin was then extracted, sonicated and immunoprecipitated using rabbit polyclonal antibodies against an HA antibody. The forward and reverse primer sets (7+8 and 9+10) amplified strong 225 bp amplicons from the input sample (Fig. 24B, input lane) and immunoprecipitates (Fig. 24B, +lane).
- SALL4 was able to bind the cis-regulatory elements of Bmi-1 in embryonic stem cells, HEK 293 cells, an acute leukemic cell line (NB4), and two AML human samples including MO (FAB classification) and AML transformed from CML (chronic myeloid leukemia) using ChIP-on- ChIP assays was also demonstrated.
- SALL4 is able to affect the levels of endogenous Bmi-1 expression
- SALL4 expression was attenuated in a leukemic cell line, HL60, using siRNA-mediated knockdown.
- siRNA retroviral constructs that target different regions of the SALL4 mRNA were made, and their ability to knockdown
- SALL4 mRNA in HL60 cells was confirmed by QRT-PCR.
- Cells from the HL-60 leukemia cell line were infected with the virus collected after 48 hr of transduction. Stable infected cells were identified under G418 selection.
- down regulation of SALL4 significantly reduced Bmi-1 levels (Fig. 25A).
- SALL4 mRNA levels were knocked down by more than 90%, and Bmi-1 expression was reduced by 75-85%.
- WESTO 1413050 1 356077-000029 Expression of high levels of SALL4 expression in human AML is associated with the expression of high levels of Bmi-1
- ChIP analysis was then performed on 32D cells that had been transfected with SALL4A constructs tagged with HA, or a control vector, and then immunoprecipitated through ChIP using antibodies specific for histone H3-K4 trimethylation and H3-K79 dimethylation.
- DNAs recovered from these ChIP experiments were amplified by Q-PCR using primers that covered 1.5kb of the Bmi-1 promoter. Consistent with binding of SALL4 to Bmi-1 promoter sites in the 32D cells transfected with SALL4A or SALL4B constructs, H3-K4 trimethylation was detected and increased roughly 2-3 folds as compared to a vector control (Fig. 27). Similar analysis with H3- K79 methylation revealed robust methylation at SALL4 binding sites and closely paralleled the pattern of H3-K4 trimethylation in the presence of SALL4.
- Example 5 SALL4 is expressed only in spermatogonia of the testis
- SALL4 is a stem cell gene acting as a gatekeeper in control of early embryonic development. Expression of SALL4 is down-regulated when ESCs are triggered to differentiate and is completely suppressed in normal somatic cells of differentiated tissues. The presence of
- SALL4 WEST ⁇ 214130 5 0.1 3 5 6077-000029 SALL4 was tested by immunohistochemistry in the testis using an antibody against SALL4. A strong nuclear staining was found in the primordial germ cells of the testis, spermatogonia, whereas the later developmental stages of spermatozoa in seminiferous tubules were negative. In addition, Sertoli cells, leydig cells, and other supporting cells were SALL4 negative.
- SALL4 is a biomarker for GCTs
- testicular GCTs WEST ⁇ 214130 50 . l 3 5 6077-000029 in normal testicular tissue.
- SALL4 was one of most informative immunohistochemistry markers in identifying GCTs.
- testis stem cells, the spermatogonia are the testicular GCTs of origin.
- SALL4 is expressed in very early ESCs, and GCTs are reported to arise from the transformation of these cells.
- SALL4 is a key regulator of self-renewal in ESCs
- NTERA2 cells an embryonic carcinoma cell line
- retinoic acid a known inducer of differentiation in embryonic carcinoma cells.
- Retinoic acid treatment resulted in a significant reduction in SALL4 expression (Fig. 28) as well as its downstream target, Bmi-1.
- Q-RT-PCR quantitative real-time polymerase chain reaction
- NTERA2 cells were treated with 5 um retinoic acid for 24-48 hrs predominately an up-regulation of a panel of ectoderm markers was observed (Fig. 28A).
- some endodermal, mesodermal, and trophectodermal genes were also up-regulated.
- SALL4 expression and its downstream target, Bmi-1 were significantly reduced when compared with untreated NTREA2 cells (Fig. 28B).
- SALL4 siRNA small interfering ribonucleic acid
- SALL4 mRNA and Bmi-1 mRNA levels were reduced by more than 90%.
- these SALL4 siRNA treated NTERA2 cells appeared to grow slowly and they were unable to differentiate further (Fig. 29B).
- caspase-3 one the key protein markers for the apoptosis pathway.
- the level of caspase-3 induced by S ALL4 knockdown was measured by flow cytometry.
- WT wild-type
- Fig 30A and 30B Similar results were observed in other cancer cell lines, such as NB4, an AML cell line.
- Kuhnlein, R.P. et al. spalt encodes an evolutionarily conserved zinc finger protein of novel structure which provides homeotic gene function in the head and tail region of the Drosophila embryo. Embo J 13, 168-79 (1994).
- AMLl/MDSl/EVIl fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Proc Natl Acad Sci U S A 97, 1760-5 (2000).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2690725A CA2690725A1 (en) | 2007-06-01 | 2008-05-30 | Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds) |
JP2010510523A JP2010528620A (en) | 2007-06-01 | 2008-05-30 | Method for targeting SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS) |
EP08756538A EP2167684A4 (en) | 2007-06-01 | 2008-05-30 | Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds) |
AU2008259976A AU2008259976A1 (en) | 2007-06-01 | 2008-05-30 | Targeting of SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/809,871 US20080241110A1 (en) | 2005-11-29 | 2007-06-01 | Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS) |
US11/809,871 | 2007-06-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008151035A2 true WO2008151035A2 (en) | 2008-12-11 |
WO2008151035A3 WO2008151035A3 (en) | 2009-01-29 |
Family
ID=40094374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/065349 WO2008151035A2 (en) | 2007-06-01 | 2008-05-30 | Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds) |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080241110A1 (en) |
EP (1) | EP2167684A4 (en) |
JP (1) | JP2010528620A (en) |
AU (1) | AU2008259976A1 (en) |
CA (1) | CA2690725A1 (en) |
WO (1) | WO2008151035A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2609193A2 (en) * | 2010-08-23 | 2013-07-03 | The Research Foundation Of State University Of New York | Method for expansion of stem cells and the use of such cells |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010042800A1 (en) * | 2008-10-10 | 2010-04-15 | Nevada Cancer Institute | Methods of reprogramming somatic cells and methods of use for such cells |
SG11201400499PA (en) | 2011-09-20 | 2014-06-27 | Brigham & Womens Hospital | Sall4 and uses thereof |
US20140273016A1 (en) * | 2013-03-14 | 2014-09-18 | William Michael Schopperle | Device and method for the detection and diagnosis of aggressive and metastatic cancer and cancer stem cells employing podocalyxin and tra biomarkers |
JP2017184623A (en) * | 2016-04-01 | 2017-10-12 | 公益財団法人ヒューマンサイエンス振興財団 | EVALUATION METHOD OF DIFFERENTIATION TENDENCY AMONG UNDIFFERENTIATED CELLS, SALL3 mRNA AS EVALUATION MARKER FOR DIFFERENTIATION TENDENCY, AND METHOD OF CONTROLLING DIFFERENTIATION ABILITY OF UNDIFFERENTIATED CELLS |
WO2019140088A1 (en) * | 2018-01-12 | 2019-07-18 | Celgene Corporation | Methods for screening cereblon modifying compounds |
CN110592211A (en) * | 2019-08-15 | 2019-12-20 | 南开大学 | Application of gene FOXD4 in preparation of acute myelogenous leukemia diagnostic kit and kit |
CN111713450B (en) * | 2020-05-26 | 2022-07-12 | 上海交通大学医学院 | Method for establishing PDX model of chronic granulocytic leukemia |
CN113142130B (en) * | 2021-03-12 | 2022-11-04 | 山东融发生物科技开发有限公司 | Disease-resistant pig breeding method |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066752A2 (en) * | 2000-03-07 | 2001-09-13 | Whitehead Institute For Biomedical Research | Reproduction-specific genes |
US20070015271A1 (en) * | 2002-04-04 | 2007-01-18 | Rosen Craig A | Human secreted proteins |
DE602004015064D1 (en) * | 2003-01-06 | 2008-08-28 | Wyeth Corp | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF COLONY CANCER |
US20050181381A1 (en) * | 2003-04-18 | 2005-08-18 | University Of Massachusetts | Prognosis, diagnosis and treatment of bone marrow derived stem cell associated cancer |
EP2273271A3 (en) * | 2004-04-23 | 2011-04-13 | Rigshospitalet, Copenhagen University Hospital | Use of novel biomarkers for detection of testicular carcinoma in situ and derived cancers in human samples |
WO2007064696A2 (en) * | 2005-11-29 | 2007-06-07 | Nevada Cancer Institute | Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds) |
-
2007
- 2007-06-01 US US11/809,871 patent/US20080241110A1/en not_active Abandoned
-
2008
- 2008-05-30 AU AU2008259976A patent/AU2008259976A1/en not_active Abandoned
- 2008-05-30 EP EP08756538A patent/EP2167684A4/en not_active Withdrawn
- 2008-05-30 JP JP2010510523A patent/JP2010528620A/en active Pending
- 2008-05-30 CA CA2690725A patent/CA2690725A1/en not_active Abandoned
- 2008-05-30 WO PCT/US2008/065349 patent/WO2008151035A2/en active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of EP2167684A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2609193A2 (en) * | 2010-08-23 | 2013-07-03 | The Research Foundation Of State University Of New York | Method for expansion of stem cells and the use of such cells |
EP2609193A4 (en) * | 2010-08-23 | 2014-02-26 | Univ New York State Res Found | Method for expansion of stem cells and the use of such cells |
US9309496B2 (en) | 2010-08-23 | 2016-04-12 | The Research Foundation For The State University Of New York | Method for expansion of stem cells and the use of such cells |
Also Published As
Publication number | Publication date |
---|---|
US20080241110A1 (en) | 2008-10-02 |
CA2690725A1 (en) | 2008-12-11 |
JP2010528620A (en) | 2010-08-26 |
WO2008151035A3 (en) | 2009-01-29 |
AU2008259976A1 (en) | 2008-12-11 |
EP2167684A4 (en) | 2010-12-29 |
EP2167684A2 (en) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080241110A1 (en) | Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS) | |
US7790407B2 (en) | Targeting of SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS) | |
Chen et al. | The Vg1-related protein Gdf3 acts in a Nodal signaling pathway in the pre-gastrulation mouse embryo | |
Cui et al. | Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia | |
US7563619B2 (en) | Mammary stem cell marker | |
Hilliard et al. | Tight regulation of p53 activity by Mdm2 is required for ureteric bud growth and branching | |
WO2005053512A2 (en) | Animal models of pancreatic adenocarcinoma and uses therefor | |
Smeets et al. | Fli-1 overexpression in hematopoietic progenitors deregulates T cell development and induces pre-T cell lymphoblastic leukaemia/lymphoma | |
JP7069147B2 (en) | Methods and Compositions for Identifying and Treating Small Cell Lung Cancer Patients | |
US7273927B2 (en) | Mdm2 splice variants | |
Jackson et al. | The Haematopoietically-expressed homeobox transcription factor: roles in development, physiology and disease | |
EP1913397A1 (en) | Graded expression of snail as marker of cancer development and dna damage-based diseases | |
Hill et al. | Cell-of-origin epigenome underlies SS18:: SSX-mediated transformation | |
Jaune-Pons et al. | EZH2 deletion does not impact acinar cell regeneration but restricts progression to pancreatic cancer in mice | |
Basheer | The Role of EZH2 in the Induction and Maintenance of Acute Myeloid Leukaemia | |
Thompson | Development of Transgenic and Allograft Mouse Models of Ependymoma | |
Kabacaoglu | Understanding the function of NF-κB transcription factor c-Rel in pancreatic cancer | |
Rose | Zebrafish Model of Uveal Melanoma | |
FENG | Roles of SETD4 in radiation sensitivity and tumorigenesis | |
Artibani | WT1 role in mammary gland and breast cancer biology | |
Ferrari | Investigating RUNX transcription factors in mammary gland development and breast cancer | |
Wensman | Differences in plasticity and expression of developmental genes in canine mammary Carcinomas and Sarcomas | |
Lee | Cell of origin in pancreatic ductal adenocarcinoma | |
Mallardo | Dissecting the role of the cytoplasmic mutant Nucleophosmin in acute myeloid leukaemia development | |
JP2007330205A (en) | Method for producing and acquiring cancer stem cell and method for screening antileukemic medicine by targeting the same stem cell |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08756538 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010510523 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008259976 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2690725 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008756538 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008259976 Country of ref document: AU Date of ref document: 20080530 Kind code of ref document: A |